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INTRODUCTION  
Sepsis is a frequent cause of admission to intensive care 
units
 
(ICUs)/ Medical wards and one of the leading causes of death among 
hospitalized patients. With an estimated annual mortality of between 30 
and 50 deaths per 100 000 population, this condition ranks in the top 10 
causes of death,  affects all ages, and occurs in the community, in long 
term care facilities, and among patients admitted to hospital under the care 
of any, and every, medical specialty. Over the last 100 years, huge 
advances have been made in the
 
field of sepsis in terms of 
pathophysiology, epidemiology, diagnosis,
 
monitoring, and therapeutics. 
Despite these changes, mortality rates remain unacceptably high
 
and 
continued progress, particularly in early d iagnosis and
 
therapy, is urgently 
needed. 
  
Sepsis encompasses a spectrum of illness that ranges from minor 
signs and symptoms through to organ dysfunction and shock. The 
pathophysiology of sepsis arises largely from the response of the host's 
innate immune system, under the influence of genetic factors. The signs 
and symptoms of sepsis are influenced by the virulence of the pathogen, 
the portal of entry, the susceptibility and response of the host, and the 
temporal evolution of the condition. 
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Categorization of patients within the subgroups
 
of severity has 
clinical
 
and prognostic significance and has improved the conduct and 
interpretation of epidemiologic studies
 
and clinical trials in the field of 
sepsis. Several risk factors for death of patients
 
with sepsis have been 
shown and those variables
 
characterizing underlying disease or associated 
with acute illness
 
and characteristics
 
of infection were associated with 
mortality.  
Sepsis is a clinical diagnosis; microbiological investigations are 
commonly negative. Powerful molecular biological techniques are likely to 
make a substantial contribution to the diagnosis of sepsis in the next five to 
10 years. 
The present study aims to determine the incidence, risk factors, co 
morbid conditions and infection characteristics for hospital mortality after 
categorizing them in three stages of severity (SIRS/Sepsis, severe sepsis, 
and septic shock) and APACHE-II scoring for comparing the outcomes in 
these  patients in a therapy-independent fashion .  
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AIMS AND OBJECTIVES   
 
 To describe the epidemiology of sepsis syndrome in the
 
tertiary care 
hospital-medical ward setting. 
 The incidence of SIRS/Sepsis, severe sepsis and septic shock in 
1000 consecutive patients admitted to the hospital and treated in the 
medical wards. 
 To evaluate and define the patient’s characteristics and etiology of 
SIRS/Sepsis spectra. 
 To examine risk factors associated with outcome in SIRS/Sepsis 
spectra. 
 To determine the co morbidities influencing the prognosis of septic 
patients. 
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REVIEW OF LITERATURE 
The last 100 years have seen great advances in our understanding
 
of 
sepsis, a term derived from the ancient Greek for rotten
 
flesh and 
putrefaction. In 2735 BC, Chinese emperor Sheng Nung recorded the use 
of an herbal remedy to treat fever. Over the next 2 millennia, pandemics of 
cholera, plague (black death), smallpox, measles, tuberculosis, and 
gonorrhea spread worldwide, wiping out huge segments of the population.  
In 1546, Hieronymus Fracastorius suggested germ theory for 
infections. In the 1680s, some of the first descriptions
 
of bacteria, 
Leeuwenhoek's "animalcules" were made, but it
 
was another 200 years 
before the link between bacteria and infection
 
finally began to be realized 
by some of the founders of modern
 
microbiology and medicine, including 
Koch, Pasteur, Semmelweis,
 
and Lister. In 1879, Louis Pasteur 
identified Streptococcus bacteria as the cause of puerperal sepsis. In 1892, 
Richard Pfeiffer identified the toxin that causes shock in patients. John 
Pringle, a British army surgeon, proposed the concept of antisepsis for the 
first time. In the 19th century, antiseptic practices lead to a reduction in 
mortality from puerperal fever from 13.6% to 1.5% in a Vienna hospital.  
In 1928, Alexander Fleming recognized that his bacterial cultures 
were killed by a blue mold, Penicillium notatum. Thus, with the discovery 
of penicillin, a new era began, with antibiotics used to treat bacterial 
10 
 
infections. In 1944 in the United States, Waksman discovered that 
streptomycin was effective in the treatment of tuberculosis. 
Sir William Osler was the first to recognize that ―except on few 
occasions, the patient appears to die from the body’s response to infection 
rather than from the infection.‖ In 1914, Schottmueller
1
  wrote, 
"Septicemia is a state of microbial invasion from a portal of entry into the 
blood stream which causes sign of illness, changing our modern 
understanding
 
of the term "sepsis"
2
. 
 
EPIDEMIOLOGY OF SEPSIS/INCIDENCE 
Current
 
estimates suggest that that some 750,000 cases of severe 
sepsis
 
occur annually in the United States, with a mortality rate of
 
around 
29%
3
. The recent Sepsis Occurrence in Acutely Ill
 
Patients (SOAP) study 
across Europe reported that more than
 
35% of intensive care unit (ICU) 
patients had sepsis at some
 
point during their ICU stay, with a mortality 
rate of 27% 
4
.The rates of sepsis appear to be increasing in hospitals 
worldwide.  
11 
 
 
A study conducted in India
5
 showed SIRS with organ dysfunction in 
25%, of which 52.77% were due to sepsis. The incidence of severe sepsis 
was 16.45%. 57.71% were male. ITU mortality of all admissions was 
12.08% and that of severe sepsis was 59.26%.  
The estimated incidence of  patients admitted to ICU with severe 
sepsis in The Netherlands was 8,643 per year. In 1986 Verbrugh and 
coworkers,  identified 5.4 cases of bacteraemia with clinical symptoms for 
every 1000 hospital admissions in two general hospitals
6
  and in 1993 
Kieft and colleagues
7
, found an incidence of sepsis syndrome in a Dutch 
university hospital of 1.36% of all hospital admissions. In 1994 the 
National Institute for Public Health and the Environment reported 4.8 cases 
of sepsis registered as first or second diagnoses for every 1000 hospital 
admissions on the basis of National Medical Registration in The 
12 
 
Netherlands
8
. The cross-sectional prevalence of severe sepsis patients in 
Dutch Intensive Care Units was 29.5%. The most severe sepsis patients 
were admitted to the ICU due to acute infection
9
.  
Sepsis and multiple organ failure are common complications in 
intensive care unit (ICU) patients and are associated with considerable 
morbidity and mortality. Sepsis affects some 40% of ICU admissions, 
severe sepsis occurs in about 30%, and septic shock in 15%. Recent 
consensus has improved the definition of sepsis and proposed a new 
classification system based on number of organ dysfunction
10
. 
 Clinically suspected sepsis and confirmed severe sepsis occurred in 
9.0 and 6.3 of 100 French ICU admissions, respectively. The 28-day 
mortality was 56%  in patients with severe sepsis, and 60% in those with 
culture-negative severe sepsis
11
. The calculated incidence of severe sepsis 
in adults treated in Australian and New Zealand ICUs is 0.77 (0.76-0.79) 
per 1000 of population. 26.5% of patients with severe sepsis died in ICU, 
32.4% died within 28 days of the diagnosis of severe sepsis and 37.5% 
died in hospital
12
. Prevalence of infections in intensive care units in 
Mexico were 58.2%
13
. 
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AGE RELATION 
Incidence increased >100-fold with age (0.2/1,000 in children to 
26.2/1,000 in those >85 yrs old). Mortality was 28.6% and also increased 
with age, from 10% in children to 38.4% in those >85 yrs old. Women had 
lower age-specific incidence and mortality, but the difference in mortality 
was explained by differences in underlying disease and the site of 
infection. The incidence was projected to increase by 1.5% per annum
14
. 
CATEGORIZATION 
Since 1992, epidemiological and clinical studies have classified 
severe infections into three categories: sepsis, severe sepsis and septic 
shock. Microbiological documentation is not always documented with 
sepsis.  The in-hospital mortality rate increased with severity, from 20% 
for sepsis to 40% for severe sepsis and 60% for septic shock, but also 
depended on the origin of infection
15
. Clinical characteristics that relate to 
the severity of sepsis include an abnormal host response to infection, the 
site and type of infection, the timing and type of antimicrobial therapy, the 
offending organism, and the development of shock, underlying disease, the 
patients' chronic health condition, and the number of failed organs
16
.  
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The prevalence of SIRS is very high, affecting one-third of all in-
hospital patients, and >50% of all ICU patients. The prevalence of 
infection and bacteraemia increases with the number of SIRS criteria met, 
and with increasing severity of the septic syndromes. About one-third of 
patients with SIRS have or evolve to sepsis. Sepsis may occur in 
approximately 25% of ICU patients, and bacteraemic sepsis in 10%. In 
such patients, sepsis evolves to severe sepsis in >25% of cases, non-ICU 
patients. Severe sepsis and septic shock occur in 2%-3% of ward patients 
and 10%-15% or more ICU patients. 25% of patients with severe sepsis 
have shock. There is a graded severity from SIRS to sepsis, severe sepsis 
and septic shock, with an associated 28-d mortality of approximately 10%, 
20%, 20%-40%, and 40%-60%, respectively. Mortality rates are similar 
within each stage, whether infection is documented or not, and 
microbiological characteristics of infection do not substantially influence 
outcome, although the source of infection does. About three of four deaths 
occur during the first months after sepsis
17
. About 28% of infections were 
associated with sepsis, 24% with severe sepsis and 30% with septic shock.  
Crude hospital mortality rates ranged from 16.9% in non-infected patients 
to 53.6% in patients with hospital-acquired infections
18
.  
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In the BASES study
19
 the overall 28-day mortality rate was 21.8%. 
The incidence density rates for sepsis, severe sepsis and septic shock were 
61.4, 35.6 and 30.0 per 1000 patient-days, respectively. The mortality rate 
of patients with SIRS, sepsis, severe sepsis and septic shock increased 
progressively from 24.3% to 34.7%, 47.3% and 52.2%, respectively. For 
patients with SIRS without infection the mortality rate was 11.3%. The 
main source of infection was lung/respiratory tract
19
.SIRS occurs more 
frequently and its occurrence ranges from 40% to 70% of all patients.10% 
of patients in the ICU suffer from sepsis, 6% from severe sepsis and 2-3% 
from septic shock. The overall prognosis is still poor, despite the recent 
advances in treatment. The mortality rate of SIRS ranges from 6% to 7% 
and in septic shock amounts to over 50%
20
.  In England 27.1% of adult 
intensive care unit admissions met severe sepsis criteria, most were 
nonsurgical (67%), and the most common organ system dysfunctions were 
seen in the cardiovascular (88%) and respiratory (81%) systems. 47% died 
during their hospital stay. Hospital mortality rate ranged from 17% in the 
16-19 age group to 64% in those >85 yrs
21
. Sepsis was more common 
among men than among women. Gram-positive bacteria becoming the 
predominant pathogens after 1987.    
 
16 
 
Organ failure contributed cumulatively to mortality, with temporal 
improvements in survival among patients with fewer than three failing 
organs
22
.  
SITE OF INFECTION 
3–10% of the patients admitted to either medical or surgical ICUs 
suffer from bacteremia and/or sepsis of different severities.  The primary 
infectious site causing sepsis has changed with
 
time, from the abdomen as 
primary source before 1990 to the
 
lungs in more recent years
23
. Recent 
studies indicate that
 
pneumonia is the most common infection associated 
with sepsis
 
today (  40%), followed by intra -abdominal infection (20%), 
catheters
 
and primary bacteremias (15%), and the urinary tract (10%)
24
.   
The Incidence of sepsis syndrome has increased, most likely due to the 
augmented use of Immunosuppressive therapies and invasive diagnostic as 
well as therapeutic procedures (e.g. catheters etc.). Site of infection was 
pulmonary in 50.3% and abdominal in 19.3%
25
. In an International 
multicentre study the Respiratory, digestive, urinary tracts, and primary 
bloodstream infections represented about 80% of all sites.  Hospital-
acquired and ICU-acquired infections are documented more frequently 
microbiologically than community-acquired infections. Infections are 
documented microbiologically in community-acquired infections in 55%
26
.  
In particular, abdominal sepsis exhibits the highest mortality rate with 
17 
 
72%
27
.  In Mexico Community-acquired infection was 23.9%.  The most 
frequently reported infections were pneumonia (39.7%), urinary tract 
infections (20.5%), wound infection (13.3%), and bacteremia (7.3%)
28
. 
ETIOLOGY/MICROBIOLOGY 
The microbiology of severe sepsis and septic shock
 
has also altered 
over time. Although in the past gram-negative
 
organisms were most 
commonly implicated, increasingly gram-positive
 
organisms are isolated, 
such that roughly similar numbers
 
of gram-positive and gram-negative 
organisms are now associated
 
with sepsis. Sepsis can also be caused by a 
fungal or parasitic
 
infection, and in about one-third of patients, no 
infectious
 
agent is identified
29
, usually either because sampling is
 
impossible          (e.g., some patients have community-acquired lung
 
infection without sputum production) or because culture remains
 
negative 
in patients who are already receiving antimicrobial
 
drugs.
  
18 
 
  
In the Indian study Culture positivity was found in 61.6%. The lung 
was the predominant source of sepsis (57.45%). Gram-negative organisms 
were responsible for 72.45% of cases and Gram-positive for 13.13%. The 
rest were parasitic, viral and fungal infection. Severe sepsis was commoner 
in Indian ITUs
3
. ITU mortality was higher compared with western 
literature. Gram-positive infections were less common although incidences 
of parasitic and viral infection were higher than in the West. 
Only three of four patients presenting with clinically suspected 
severe sepsis have documented infection. However, patients with clinically 
suspected sepsis but without microbiological documentation and patients 
with documented infection share common risk factors and are at similarly 
high risk of death. In addition to the severity of illness score, acute organ 
19 
 
failures and the characteristics of underlying diseases account for 
stratification of patients and outcome
30
. 
SEASONAL INCIDENCE 
The incidence and mortality of sepsis and severe sepsis are seasonal 
and consistently highest during the winter, predominantly related to 
respiratory sepsis. Seasonal changes in sepsis incidence vary according to 
geographic region
23
. The mechanisms underlying these differences require 
further investigation. Understanding seasonal or regional variations may 
improve knowledge of sepsis epidemiology and pathophysiology and 
could affect healthcare planning and resource allocation.  
RISK FACTORS 
Risk factors for severe sepsis and septic shock
31
  
1.   Extremes of age (<10 y and >70 y) 
2. Primary diseases (Liver cirrhosis, Alcoholism, Diabetes 
mellitus, Cardiopulmonary diseases, Solid malignancy, 
Hematologic malignancy, Immunosuppression, Neutropenia, 
Immunosuppressive therapy, Corticosteroid therapy, 
Intravenous drug abuse, Complement deficiencies, Asplenia) 
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3.   Major surgery, trauma, burns. 
4.   Invasive procedures (Catheters, Intravascular devices,    
Prosthetic devices, Hemodialysis and peritoneal dialysis    
catheters, Endotracheal tubes) 
5.   Prior antibiotic treatment 
6.   Other factors - Childbirth, abortion, and malnutrition 
Several risk factors for severe sepsis have been identified in 
previous studies, including age, sex, comorbidities, and causative 
pathogen
32,33
.  Major determinants of both early (<3 days) and secondary 
deaths in the whole cohort were the Acute Physiology Score and the 
number of acute organ system failures.  Other risk factors for early death 
included a low arterial blood pH (<7.33) (P < .001) and shock (P = .03), 
the admission category (P < .001), a rapidly or ultimately fatal underlying 
disease  (P < .001), a preexisting liver (P = .01) or cardiovascular             
(P = .002) insufficiency, hypothermia (P = .02), thrombocytopenia           
(P = .01), and multiple sources of infection (P = .02). In patients with 
documented sepsis, bacteremia was associated with early mortality           
(P = .03)
34
. 
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Other independent mortality risk factors in a French study were 
mechanical ventilation (OR = 4.97), chronic alcoholism (OR = 3.38), age 
>65 years (OR = 2.65), prothrombin ratio <40% (OR = 2.37), and 
PaO2/FiO2 ratio <150 (OR = 1.91). These six mortality risk factors allow 
screening immediately septic shock patients with a high mortality risk
35
.  
The major determinants of outcome, both short-term and long-term, of 
patients with sepsis are the severity of underlying diseases and co 
morbidities, the presence of shock and organ failures at onset of sepsis or 
evolving thereafter
36
.  Multivariate regression analysis have also showed 
the following risk factors for acquired infections: neurologic failure as a 
primary cause of admission, number of therapeutic and/or diagnostic 
interventions during the preceding week, peripherally administered 
infusion of hyperosmolar solutions, sedative usage in the preceding week. 
The administration of antimicrobial treatment if there was an infection 
decreased the risk of death
37
.  
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DEFINITIONS  
An American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference was held in North-brook in 
August1991with the goal of agreeing on a set of definitions that should be 
applied to patients with sepsis and its sequelae.  Definitions for severe 
sepsis, septic shock, hypotension, and multiple organ dysfunction 
syndrome were also offered. The current definitions are from The Sepsis 
definitions conference held in
 
2001, sponsored by the SCCM, the ACCP, 
the American Thoracic
 
Society, the European Society of Intensive Care 
Medicine, and
 
the Surgical Infection Society
38
. 
The term sepsis in popular usage implies a clinical response arising 
from   infection. It is apparent that a similar, or even identical, response 
can arise in the absence of infection.  Systemic inflammatory response 
syndrome (SIRS) describes this inflammatory process, independent of its 
cause. 
23 
 
 
Figure:1  The Interrelationship between systemic inflammatory response 
syndrome (SIRS), Sepsis and infection  
BACTEREMIA: The presence of visible bacteria in the blood. 
INFECTION: Microbial phenomenon characterized by an inflammatory 
response to the presence of micro-organisms or the invasion of normally 
sterile host tissue by those organisms. 
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS): The 
systemic inflammatory response to a variety of severe clinical insults. The 
response is manifested by two or more of the following conditions:   
 Temperature >38ºC or <36ºC 
 Heart rate >90 beats per minute 
 Respiratory rate >20 beats per minute or PaCO2 <32 mmHg 
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 WBC count >12,000/cu.mm, <4000/cu.mm or >10% 
immature band forms. 
 Hyperglycemia (Plasma glucose > 120 mg/dl or 7.7 mmol/l) 
without DM 
SEPSIS: The systemic response to infection, manifested by two or more of 
the above criteria’s as a result of infection, documented microbiologically 
or strongly clinically suspected. 
MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS): Presence 
of altered organ function in an acutely ill patient such that homeostasis 
cannot be maintained without intervention. 
SEVERE SEPSIS: Sepsis associated with organ dysfunction, 
hypoperfusion or hypotension. Hypoperfusion and perfusion abnormalities 
may include, but are not limited to lactic acidosis, oliguria, or an acute 
alteration in mental status. 
SEPSISI INDUCED HYPOTENSION: SBP <90 mmHg or a reduction of 
>40mmHg from baseline in the absence of other causes of hypotension. 
 SEPTIC SHOCK: Sepsis induced hypotension despite adequate fluid 
resuscitation along with the presence of perfusion abnormalities  defined 
above. Patients receiving vasopressors or inotropes may not be 
hypotensive at the time the perfusion abnormalities are measured.   
25 
 
MODS may be described as being either primary or secondary. 
MODS develop by two relatively distinct, but not mutually exclusive, 
pathways. Primary MODS is the direct result of a well-defined insult in 
which organ dysfunction occurs early and can be directly attributable to the 
insult itself. An example of primary MODS is organ dysfunction as the 
immediate result of trauma (e.g., pulmonary contusion, renal failure due to 
rhabdomyolysis, or the coagulopathy due to multiple transfusions). In 
primary MODS, the participation of an abnormal and excessive host 
inflammatory response in both the onset and progression of the syndrome 
is not as evident as it is in secondary MODS.  
Secondary MODS develops, not in direct response to the insult 
itself, but as the consequence of a host response, and is identified within 
the context of SIRS. SIRS is also a continuous process, and describes an 
abnormal host response that is characterized by a generalized activation of 
the inflammatory reaction in organs remote from the initial insult. When 
the process is due to infection, the terms sepsis and SIRS are synonymous. 
Given that SIRS/sepsis is a continuous process, MODS may be understood 
to represent the more severe end of the spectrum of severity of illness that 
characterizes SIRS/sepsis. Thus, secondary MODS usually evolve after a 
latent period following the inciting injury or event, and is most commonly 
seen to complicate severe infection.  
26 
 
  
 
TABLE 2. THE PIRO CONCEPT
39
 
                     Clinical       Other Tests 
 
P (predisposition) Age, alcohol abuse, steroid or 
immunosuppressive therapy 
Immunologic monitoring, 
genetic factors 
I (infection) Site-specific (e.g., pneumonia, 
peritonitis) 
X-rays, CT scan, 
bacteriology 
R (response) Malaise, temperature, heart rate, 
respiratory rate 
WBC, CRP, PCT, 
modified APTT 
O (organ dysfn) Arterial pressure, urine output, 
Glasgow coma score 
PaO2/FIO2, creatinine, 
bilirubin, platelets 
 
Definition of abbreviations: APTT = activated partial 
thromboplastin time; CRP = C-reactive protein; CT = computed 
tomography; PCT = procalcitonin; WBC = white blood cell count. 
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PATHOPHYSIOLOGY OF SEPSIS
40-52
 
The pathogenesis of sepsis involves a complex process of cellular
 
activation resulting in the release of proinflammatory mediators,
 
such as 
cytokines, activation of neutrophils, monocytes, and
 
microvascular 
endothelial cells, involvement of neuroendocrine
 
reflexes, and activation of 
the complement, coagulation, and
 
fibrinolytic systems.  
Initiation of sepsis occurs as microbial
 
components are recognized 
by soluble or cell-bound pattern recognition
 
molecules or receptors, such 
as CD14 and Toll-like receptors
 
(TLRs), activation of which induces the 
transcription of inflammatory
 
and immune response genes, often via 
nuclear factor- B–mediated
 
mechanisms, resulting in the release of a 
number of endogenous
 
mediators.  
Cytokines, a family of cell signaling peptides with
 
pro-and anti 
inflammatory properties, are some of the best known
 
and most studied 
endogenous mediators associated with the development
 
of organ system 
dysfunction in sepsis.
 
Two of the first cytokines to be implicated in sepsis 
were tumor
 
necrosis factor (TNF- ) and interleukin 1 (IL-1).  
TNF- , first
 
identified in 1975, is involved in leukocyte adhesion, 
local
 
inflammation, neutrophil activation, generation of fever, suppression
 
of erythropoiesis, decrease in fatty acid synthesis, and suppression
 
of 
albumin synthesis, among others. The final critical steps
 
demonstrating that 
these cytokines were involved in the development
 
of severe sepsis came 
28 
 
from studies showing that there was a
 
correlation between the magnitude 
of circulating TNF-  levels
 
and patient outcome, and then the observation 
that the
 
injection of IL-1 or TNF-  into animals can reproduce all the
 
hemodynamic and biochemical features of severe sepsis and organ
 
failure. 
Furthermore, blocking the effects of TNF and IL-1 in
 
models of severe 
infection prevented complications and improved
 
outcomes. Other 
cytokines and proinflammatory mediators that
 
are currently attracting 
considerable interest for their putative
 
contribution to sepsis include high-
mobility group box1(HMGB1),
 
protein, a late mediator of systemic 
inflammation, and macrophage
 
migration inhibitory factor, MIF. An 
important advance in sepsis pathophysiology has been the
 
growing 
realization of the links between the coagulation system
 
and the immune 
response to sepsis, which led to the development
 
of the only specific 
antisepsis treatment currently available,
 
recombinant human activated 
protein C.  
Role of Endotoxin and Other Bacterial Toxins 
Endotoxin was first identified more than 100 years ago, but
 
it was 
not until 1951 that Borden and Hall first suggested that
 
it might have a role 
in the development of septic shock.
 
Evidence for a pathogenic role of 
endotoxin came from the report
 
by Taveira da Silva and colleagues of the 
effects of accidental
 
self-administration of endotoxin by a lab technician. 
Endotoxin is frequently found in the blood of acutely ill patients
 
with 
29 
 
sepsis, even in the absence of demonstrable gram-negative
 
infection, 
possibly as a result of bacterial translocation
 
from the gut. Even patients 
with heart failure may have circulating
 
endotoxin. Nevertheless, endotoxin 
levels are associated
 
with a higher incidence of complications and have 
been
 
shown to be an early predictor of bacteremia in febrile patients.
 
 
Other bacterial toxins, such as peptidoglycans or lipoteichoic
 
acid, 
can be released by gram-positive microorganisms and induce
 
the 
production of mediators associated with sepsis. Although
 
early studies in 
patients attempted to relate the hemodynamic
 
presentation with the type of 
microorganism (gram-positive vs.
 
gram-negative), the results of these 
studies were inconsistent, and it became apparent that the hemodynamic 
response
 
is not related to the type of organism. This does not mean,
 
however, that the specific causative organism does not matter;
 
although the 
innate immune response generated by the host may
 
be similar for all 
microorganisms, there also appear to be adaptive
 
pathogen-specific 
responses. 
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MANAGEMENT OF SEPSIS
53-64
 
In 2003, critical care and infectious disease experts representing  11  
international  organizations  developed  management guidelines   for  
severe  sepsis   and  septic   shock   that  would   be  of  practical use for 
the bedside  clinician, under the auspices of Surviving Sepsis Campaign, 
an international effort to increase awareness and improve outcome in 
severe sepsis.  In  2003, critical care and infectious disease experts 
representing 11  international organizations developed management 
guidelines for  severe  sepsis   and  septic shock  that would  be of practical 
use for the bedside  clinician, under the auspices of the Surviving Sepsis 
Campaign, an international effort to increase awareness and improve 
outcome in severe sepsis. 
Key   recommendations,  listed by category and not by hierarchy,   
include  early  goal-directed    resuscitation   of the   septic patient during 
the first 6 hrs after recognition; appropriate diagnostic studies to ascertain 
causative organisms before starting antibiotics; early administration of 
broad-spectrum antibiotic therapy; reassessment of antibiotic therapy with  
microbiology   and  clinical  data  to narrow coverage, when appropriate;  a 
usual 7–10 days of antibiotic therapy guided by clinical response; source 
control with attention to    the method that balances risks and benefits. 
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Every patient should be evaluated for the presence of a focus on 
infection amenable to source  control  measures, specifically the drainage 
of an abscess or local focus  on infection, the debridement of  infected 
necrotic tissue, the removal of a potentially infected device, or the 
definitive control of a source of ongoing microbial contamination If 
intravascular access devices are potentially the source of severe sepsis or 
septic shock, they should be promptly removed after establishing other 
vascular access. 
Equivalence of crystalloid  and  colloid  resuscitation
53
;  aggressive  
fluid  challenge  to  restore mean circulating filling pressure; vasopressor 
preference for norepinephrine and dopamine; cautious use of vasopressin 
pending further studies; avoiding low-dose dopamine administration for 
renal protection; consideration of dobutamine inotropic therapy in some 
clinical situations.  
Avoidance of supranormal oxygen delivery as a goal of therapy; 
stress-dose steroid therapy for septic shock; use of recombinant activated 
protein C in patients with severe sepsis and high risk for death; with 
resolution of tissue hypo- perfusion and in the absence of coronary artery 
disease or acute hemorrhage, targeting a hemoglobin of 7–9 g/dL; 
appropriate use of fresh frozen plasma and platelets.  
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A low tidal volume and limitation of inspiratory plateau pressure 
strategy for acute lung injury and acute respiratory distress syndrome; 
application of a  minimal  amount  of  positive  end-expiratory  pressure  in  
acute  lung injury/acute respiratory distress syndrome; a semirecumbent 
bed position unless contraindicated. 
Protocols for weaning and sedation/analgesia, using either 
intermittent bolus sedation or continuous infusion sedation with daily 
interruptions/lightening; avoidance of neuromuscular blockers, if at all 
possible; maintenance of blood glucose <150 mg/dL after initial 
stabilization; equivalence of continuous veno-veno hemofiltration and 
intermittent hemodialysis; lack of utility of bicarbonate use for pH >7.15; 
use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of 
limitation of support where appropriate. 
Recombinant Human Activated Protein C
54
  
 rhAPC is recommended in patients at high risk of death (Acute 
Physiology and Chronic Health Evaluation II  >25, sepsis-induced multiple   
organ failure, Septic shock, or sepsis-induced acute respiratory distress  
syndrome [ARDS] and with no absolute contraindication related to 
bleeding risk or relative contraindication that outweighs  the potential 
benefit of rhAPC. 
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TABLE 3.  SOME OF THE MANY PROPOSED SEPSIS 
THERAPIES THAT HAVE UNDERGONE CLINICAL TRIALS 
1. Antiendotoxin strategies ( HA-1A, E5,  LPS analogs). 
2. Anticytokine strategies ( Anti-TNF antibodies, TNF 
receptors, IL-1ra). 
3. Strategies against other mediators (Nitric oxide—L-
NMMA, L-NAME, methylene blue, PAF, 
acetylhydrolase, Arachidonic acid metabolites, 
Antioxidants). 
4. Strategies against coagulation system (Antithrombin III, 
Tissue factor pathway inhibitor). 
5. Enhanced elimination (Hemofiltration, Immune-
stimulating strategies, GCSF, IFN- ). 
6. Immunonutrition 
Definition of abbreviations:  
GCSF = granulocyte colony–stimulating factor;  IFN = interferon;           
IL = interleukin;   LPS = lipopolysaccharide;   PAF = platelet 
activating factor;  TNF = tumor necrosis factor. 
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MATERIALS AND METHODS 
Methods         
A prospective, observational, study was carried out over a 5 month 
period. 
Primary objectives 
 The aims were to determine the incidence of sepsis spectra 
among 1000 consecutively admitted adult patients in medical 
wards of Madras Medical College and Government General 
Hospital, Chennai.   
 To determine the mortality rates, as well as factors associated 
with the risk of death.  
 To describe the epidemiology of sepsis syndrome in the
 
tertiary 
care hospital -medical ward setting. 
 To evaluate and define the patient’s characteristics and etiology 
of SIRS/Sepsis spectra. 
 To determine the co morbidities influencing the prognosis of 
septic patients. 
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 To determine the frequency of infecting organ systems involved.  
 To determine the types of infection (acquisition and 
microbiology) involved. 
Design and data collection 
This was a prospective, observational, study.  The study protocol 
was approved by the Ethics Committee of the coordinating centre.  The 
study conducted after informed consent was obtained from participants.  
The study was carried out over a 5-month period, from May 16 to October 
16, 2010, in medical wards. 
All patients were screened for SIRS on admission and followed up 
till death or discharge. All data were collected on standardized forms in 
each ward. 
Inclusion criteria: 
1.  Age greater than 12 years. 
2.  Patients admitted in medical units in Government General 
Hospital who fulfill the following criteria for SIRS/Sepsis were 
selected for the study. 
 
 
 
 
36 
 
    Infection, documented or suspected, and any 2 of the following: 
 Fever (core temp > 38.3 °C) or Hypothermia (core temp < 36 
ºC) 
 Heart rate > 90/min or > 2 SD above the normal value for age 
Tachypnea >20/min or > 2 SD above the normal value for age 
Leukocytosis ( > 12,000/mm3) or Leukopenia (< 4,000/mm3) 
Hyperglycemia (Plasma glucose > 120 mg/dl or 7.7 mmol/l) 
without DM Altered mental status 
Exclusion  criteria   : 
1. Patients  Age  less  than 12 years 
All data related to physiological and biological variables were 
checked against standardized ranges. Inconsistent or extreme values were 
thoroughly checked and corrected before analysis. Clinical and laboratory 
data to enable the Acute Physiology and Chronic Health Evaluation 
(APACHE) II Score [20] to be calculated were collected within the first 24 
h after admission. Neurological status was determined using the Glasgow 
Coma Scale (GCS) prior to sedation.  
Patients were considered to have an infection if this was 
microbiologically documented according to the standard definitions or at 
least clinically suspected requiring evidence such as the presence of white 
blood cells in a normally sterile body fluid, perforated viscus, chest X-ray 
consistent with pneumonia and associated with purulent tracheal secretion, 
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or a clinical syndrome associated with a high probability of infection. 
Infection was classified according to the organ of acquisition (CNS, RS, 
CVS, Skin & Soft tissue infection, GIT,  GUrT, HB, Tropical infections), 
to the method of diagnosis (suspected, clinically documented through 
imaging, or microbiologically documented), to the microorganisms 
responsible when these were isolated, and to the organ(s) affected. It was 
recorded whether the initial antibiotic therapy was appropriate according to 
the antibiogram for the microorganisms responsible when these were 
isolated. 
Statistical analysis 
Quantitative data are described as mean ± standard deviation (SD), 
medians and percentiles. Comparisons were performed using the Student t 
test or the Mann-Whitney U test, as appropriate; values of p < 0.05 were 
considered significant. Categorical data were analyzed by means of 
frequencies, percentages, and their confidence intervals.  Patients were 
analyzed according to: (a) Spectral level of sepsis (at admission);               
(b) acquisition site of infection (CNS, RS, CVS, Skin & Soft tissue 
infection, GIT, GUrT, HB, Tropical infections); (c) micro-biological type 
of infection; (d) Risk factors associated with mortality were analyzed 
univariately and then multivariately by logistic regression; the degree of 
association with mortality was expressed as independent factors by means 
of odds ratios with their corresponding 95% confidence intervals.  
38 
 
The statistical analysis was carried out by a professor at the 
Department of Biostatistics of Presidency College, who did not participate 
in collecting the data. All analyses were performed using SPSS statistical 
software.  
Estimates
 
of total cases expected annually were extrapolated from 
the
 
number of cases, the period of observation, and the sampling fraction. 
Conflict of interest   : Nil. 
External Financial support : Nil 
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OBSERVATIONS AND RESULTS 
 
 
   
 
 
 
 
 
 
 
 
Out of the 1000 consecutively admitted patients 132 fulfilled the 
criteria for SIRS and were included in the study.  49.24% had sepsis, 
32.58% had severe sepsis and 18.18% had septic shock. The death rate was 
10.17% for sepsis, 18.60% for severe sepsis and 29.17% for septic shock. 
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Out of the 132 patients males were 77 and females 55. The 
incidence was the highest in the age group of 51-60 years and only in that 
age group female patients were more than male patients. 
 
The previous chart demonstrates the distribution of male and female 
patients among the different categories of sepsis.  Male patients were more 
in all the categories of sepsis.  
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The above chart reveals that the incidence of sepsis was roughly the 
same but the proportion of patients with severe illness was more with 
increased age. 
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The chart above shows the comorbidities in the various organ 
systems and the severity of illness associated with each.  Comorbidities in 
CNS, GUrT, Hepatobiliary tract, CVS had higher percentage of incidence 
of severe disease, while if no comorbid condition is present proportion was 
less. 
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 The above chart represents the distribution of the various source of 
infections in relation to the severity of sepsis. Tropical infections presented 
with milder disease predominantly while on comparison respiratory tract 
infections had higher proportion of more severe illness. 
 
44 
 
 
 
Respiratory tract remains the most common source of infection.  The 
incidence of tropical infections was 24%. Next to respiratory system, 
genitor-urinary and hepatobiliary tract were the commonest source of 
infection. 
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Gram-positive and gram-negative organisms were isolated equally 
in the various specimens. CONS were the commonest isolate followed by 
Stap.aureus. Among the gram-negative organisms E.coli and klebsiella 
were the commonest. Candida was isolated from only one case. There was 
also isolate of MRSA from two samples of the same patient.   
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Positive blood cultures were obtained in only 32% of cases.Among 
the isolates CONS and Staph.aureus were again the most common. 
Acinetobacter, E.coli,  Klebsiella and pseudomonas isolation was around 
3% each. Only 2 of the 10 cases of widal positive enteric fever cases had 
positive blood culture.  
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Positive Urine cultures were obtained in only 30% of cases.  Among 
the isolates E.coli, was the commonest.  One each of candida, CONS and 
Proteus formed the rest of the isolates. 
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Sputum cuture had an yield of 35%. Klebsiella was the most 
common organism followed by throat commensals, CONS and staph. 
Strept.pneumoniae was present in one sample and so was Mycoplasma.  
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Cultures from other sites like ascitic fluid, pleural fluid, CSF, were 
mostly negative 79%. One each of E.coli, MRSA and pseudomonas was 
obtained. Evidence of tropical infections was positive in 28 cases. 
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The death rates were higher as the age advanced. The presence of 
other comorbid conditions places them under higher risk of mortality.  The 
highest deaths were in the above 50 age group. 
 
Females had a higher proportional mortality rate. 20% vs 12.18%. 
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Proportional mortality rate were higher for multi organ system co-
morbidities, followed by underlying malignancy, hematological diseases 
and cardiovascular co-morbidities. Though the lung was the commonest 
source of infection an underlying lung disease did not increase the 
mortality rate.  
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Mortality was higher when the source of infection was the lung, 
followed by genitourinary tract and hepatobiliary tract.  Patients fared 
better when the source of infection was tropical infections, skin infections 
and nervous system infections. It is important to note that altered mental 
status at presentation carried a poorer prognosis. 
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 The more the number of organ dysfunctions the more was the 
severity of disease in the grades of sepsis. More were the number of organs 
dysfunctioning as the severity of sepsis progressed and higher was the 
mortality when a higher number of organs dysfunctioned. 
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The more the number of organ dysfunctions the poorer was the 
prognosis and more was the mortality rate. From no deaths if only one 
organ is involved to 25% mortality with 2 organs to 45.45% mortality 
when 4 organs dysfunction. 
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DESCRIPTIVE STATISTICS 
 The following table shows the minimum and maximum values of the 
variables that were used in the analysis of relation to prognosis and 
outcome. 
 
Minimum Maximum Mean Std. 
Deviation 
GCS Score 3 15 12.66 3.475 
Temperature 95.8 104.0 101.329 1.5808 
Pulse rate 90 126 106.89 8.531 
Respiratory rate 18.16 32.00 25.1897 3.14903 
pH 6.91 7.54 7.2836 .12525 
Sodium 126 146 136.55 5.764 
Potassium 2.8 4.7 3.790 .5277 
Hematocrit 22.536 43.820 34.19350 4.081372 
Total Count 1800 33800 11767.73 4301.861 
Platelet .36 2.87 1.5123 .58341 
Urea 31 162 57.14 23.237 
Creatinine .6 4.3 1.584 .9186 
Systolic – BP 60 200 113.80 26.426 
Diastolic – BP 40 120 73.42 13.864 
Blood Sugar 66 287 116.62 33.136 
Total Bilirubin .4 5.4 1.584 1.0547 
SGPT 31 214 62.53 26.624 
SAP 34 157 66.10 21.559 
Total Protein 5.0 8.3 6.326 .6591 
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The following table shows the variables with significant p values 
between the various categories of sepsis and in turn to the prognosis by 
using ANOVA. 
    
df 
Mean 
Square 
F P value 
Temperature Between Groups 2 9.028 3.765 .026 
  Within Groups 129 2.398     
pH Between Groups 2 .134 9.714 .048 
  Within Groups 129 .014     
Platelet Between Groups 2 2.760 9.113 .032 
  Within Groups 129 .303     
Urea Between Groups 2 12342.012 34.571 .041 
  Within Groups 129 357.004     
Creatinine Between Groups 2 17.392 29.612 .027 
  Within Groups 129 .587     
 
Minimum Maximum Mean 
Std. 
Deviation 
Albumin 2.0 4.9 3.322 .6207 
pO2  70.1 97.0 89.356 5.3280 
pCO2 26.0 63.1 42.686 7.7097 
Hco3- 12.0 29.0 20.286 3.8433 
PaO2/FiO2  175.3 461.9 343.727 108.8780 
Lactate 1.2 6.7 3.877 1.5501 
APACHE-II 
score 
23 53 33.39 6.482 
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df Mean 
Square 
F P value 
Systolic - BP Between Groups 2 11451.402 21.541 .036 
  Within Groups 129 531.597     
Diastolic - BP Between Groups 2 6271.315 64.015 .029 
  Within Groups 129 97.966     
Blood Sugar Between Groups 2 1501.393 1.375 .256 
  Within Groups 129 1091.754     
Total Bilirubin Between Groups 2 25.932 35.642 .044 
  Within Groups 129 .728     
SGPT Between Groups 2 11417.504 21.034 .030 
  Within Groups 129 542.804     
pO2/FiO2 Between Groups 2 532803.25
5 
141.040 .033 
  Within Groups 129 3777.688     
Lactate Between Groups 2 119.139 200.900 .045 
  Within Groups 129 .593     
APACHE-II  
score 
Between Groups 2 
1025.520 38.320 .048 
  Within Groups 129 26.762     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
The following table shows the significance in prognostication of 
individual variables between the different groups of sepsis severity. The 
corresponding p values and the confidence limit are shown.  
Dependent 
Variable 
(I) Category of 
Severity 
(J) Category of 
Severity 
P 
value 
95% Confidence 
Interval 
        
Lower 
Bound 
Upper 
Bound 
Temperature  Severe Sepsis  Septic Shock .021 .132 2.003 
pH  SIRS/Sepsis  Septic Shock .057 -.0036 .1296 
Platelet  SIRS/Sepsis  Septic Shock .016 .0559 .6792 
Urea  Severe sepsis  Septic Shock .277 -18.82 4.01 
Creatinine  Severe sepsis  Septic Shock .054 -.878 .048 
Systolic – 
BP 
SIRS/Sepsis  Severe sepsis 
.790 -13.71 7.78 
Diastolic – 
BP 
SIRS/Sepsis  Severe sepsis 
.973 -5.05 4.18 
Total 
Bilirubin  
Severe sepsis  Septic Shock 
.004 -1.220 -.190 
SGPT  Severe sepsis  Septic Shock .045 -26.27 1.88 
PaO2/FiO2  Septic Shock  Severe sepsis .544 -53.651 20.614 
Lactate  Septic Shock  Severe sepsis .919 -.542 .388 
APACHE-II 
score 
Severe sepsis Septic Shock 
.005 -7.35 -1.09 
                                           
*  The mean difference is significant at the .05 level. 
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Effect of Age Group on outcome 
  Outcome Total 
  Discharge Death   
Age Group in 
years 
Upto 20 
18 1 19 
  21-30 22 2 24 
  31-40 20 0 20 
  41-50 19 3 22 
  51-60 22 9 31 
  Above 
60 
10 6 16 
  Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.074(a) 5 .007 
Likelihood Ratio 18.024 5 .003 
Linear-by-Linear Association 11.972 1 .001 
 
 The greater the age the higher was the mortality rate as shown by 
the table above. Though the female sex had a higher proportional mortality 
rate the p values were not significant.  
The presentation of hyperglycemia in the absence of diabetes history 
carried a poorer prognosis, underlying Diabetes had a bearing on the 
outcome though it was statistically significant. More patients with DM 
succumbed to their illness whereas non diabetic status had a better chance 
of survival. 
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Effect of DM on Outcome 
    Outcome Total 
    Discharge Death   
DM Yes Count 12 12 24 
  No Count 99 9 108 
Total Count 111 21 132 
 
Effect of SHT  on Outcome 
    Outcome Total 
    Discharge Death   
SHT Yes Count 15 10 25 
  No Count 96 11 107 
Total Count 111 21 132 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.380(b) 1 .001 
Continuity Correction(a) 11.250 1 .001 
Likelihood Ratio 11.147 1 .001 
Fisher's Exact Test       
Linear-by-Linear 
Association 
13.278 1 .001 
 
The presence of Hypertension had poorer survival rates that were 
statistically significant. 
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Effect of Hypothemia  on Outcome 
    Outcome Total 
    Discharge Death   
Hypothemia Yes Count 3 2 5 
    % within Hypothemia 60.0% 40.0% 100.0% 
  No Count 108 19 127 
    % within Hypothemia 85.0% 15.0% 100.0% 
 
 The proportion of patients who died with hypothermia was more. 
The ability to mount a response by producing fever conferred survival 
advantage. As was the case with leucopenia and leucocytosis, 
hyperglycemia and hypoglycemia.  But a statistical significance was not 
got.  
Effect of Leukopenia on Outcome 
    Outcome Total 
    Discharge Death   
Leukopenia Yes Count 12 4 16 
    % within Leukopenia 75.0% 25.0% 100.0% 
  No Count 99 17 116 
    % within Leukopenia 85.3% 14.7% 100.0% 
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Effect of Hyperglycemia on Outcome 
    Outcome Total 
    Discharge Death   
Hyperglycemia Yes Count 5 2 7 
    % within 
Hyperglycemia 
71.4% 28.6% 100.0% 
  No Count 106 19 125 
    % within 
Hyperglycemia 
84.8% 15.2% 100.0% 
 
 
Effect of No. of organ dysfunction on Outcome 
  Outcome Total 
  Discharge Death   
No.of organ dysfuntion 0 59 6 65 
  1 4 0 4 
  2 24 6 30 
  3 18 4 22 
  4 6 5 11 
  Value Asymp. Sig. (2-sided) 
Pearson Chi-Square 10.562(a) .032 
Likelihood Ratio 9.610 .048 
Linear-by-Linear Association 7.353 .007 
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The number of organs that dysfunction has a strong association with 
the outcome. The p value was significant. The combinations of different 
dysfunctions were not important but the cumulative dysfunctioning of 
organ systems carried a higher mortality risk.  
Effect of Category of Severity  on Outcome 
   Outcome Total 
    Discharge Death   
Severity SIRS/Sepsis Count 59 6 65 
    % within  90.8% 9.2% 100.0% 
  Severe sepsis Count 35 8 43 
    % within  81.4% 18.6% 100.0% 
  Septic Shock Count 17 7 24 
    % within  70.8% 29.2% 100.0% 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 5.554(a) 2 .032 
Likelihood Ratio 5.362 2 .038 
Linear-by-Linear Association 5.505 1 .019 
 
 The severity of sepsis was also statistically significantly associated 
with mortality.  The higher the grading of sepsis more was the mortality 
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DISCUSSION 
The important findings of this study were: (a) the high incidence 
(13.2%) of sepsis in the medical wards and mortality (15.91%); (b) the 
factors associated with early death were higher organ dysfunctions at 
diagnosis, age, more severe category of sepsis, chronic co morbid illnesses, 
increased APACHE-II score, increased lactate levels.  
Of the 1000 consecutive admissions during the period from May to 
October 2010, in the medical wards 132 patients satisfied the criteria of 
SIRS with documented evidence or strong clinical suspicion of infection. 
They were sub- classified further into SIRS/Sepsis, Severe sepsis and 
Septic shock based upon the definitions and criteria earlier described. 
Appropriate clinical presentation, imaging techniques and cultures from 
suspected compartments were used to confirm infection.  
Standardized diagnostic criteria for sepsis, severe sepsis, septic 
shock, and organ dysfunction and failure associated with infection have 
enabled the epidemiological evaluation of septic syndromes, as well as of 
their progression in recent years and of the efficacy of new treatment 
measures. Using these diagnostic criteria, we found an incidence of Sepsis 
spectra of 13.2%, which is comparable to that of other series published in 
recent years.  
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Different authors have suggested that this progression might be 
related to the use of immunosuppressors, hospital malnutrition, alcoholism, 
cancer, diabetes mellitus, the growing invasiveness of both diagnostic and 
therapeutic measures, increased resistance of microorganisms, and the 
progressive aging of the population. The high incidence of other risk 
factors such as  diabetes, chronic heart failure, kidney failure, liver failure, 
or respiratory failure compound this increase.  
The projected incidence of sepsis spectra for the admissions covered 
by the medical wards in this hospital was 3854 per year, a figure that is 
lower than the incidence reported in recently published studies. This 
difference might be explained by seasonal bias, differences in the 
populations studied, and differences in access to hospitals.  The mortality 
in this study (15.91%) differs from that published in the most recent series, 
which ranges from 28%to 48.4%. However, methodological differences 
with our study account for much of these differences. Selection bias could 
have been a reason. More number of patients had tropical infections and all 
of them recovered uneventfully  
The incidence of sepsis spectra was 132/1000 (13.2%). Males 
formed 77 (58.33%) of the 132 and females 55 (41.66%). The incidence 
for the subsets were SIRS/Sepsis 49.24% (n=65), Severe sepsis 32.58% 
(n=43), Septic shock 18.18% (n=24). Across all age groups incidence were 
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more in the male gender. Incidence was highest in the age group of 51-60 
years.  
The Death rate was 15.91% (n=21), males 7.58% (n=10) and 
females 8.33% (n=11).The proportional death rate was higher among the 
females 20% (11/55) compared to males 12.99% (10/77).There was n 
statistical significance to this finding  and is different from the other 
studies were mortality was more in the males. Among the subsets death 
was more frequent in the septic shock group than the severe sepsis or 
SIRS/Sepsis groups. The death rates were 9.2%  18.6% and 29.2%  for 
SIRS/Sepsis, severe sepsis and septic shock respectively. The general trend 
of higher mortality with severity was as in the other studies but the 
percentage mortality rates were much lower than in those studies.  
As in other recently published series, infection was most frequently 
located in the lungs. The incidence of tropical infections was much higher 
than in any of the quoted studies. Our region is endemic for malaria, 
enteric fever and leptospirosis. The incidence of dengue which has a 
seasonal preference was peaking during the time of this study. Hence 
around 21.21% of the cases were due to these infections. The better 
outcome following these infections could have been a factor for the 
difference in values by percentage on comparison to other studies.  
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The next common sources of infections were the genitourinary tract 
infections and hepato-biliary infections. Western studies show abdominal 
causes as the second most common infecting source. Our set up caters to a 
lot of patients who have decompensated liver disorder predominantly from 
alcoholic liver disorder and viral hepatitis. These patients commonly 
present with suspicion of spontaneous bacterial peritonitis. Though the 
cytology revealed evidence of infection and fluid was exudative, 
organisms could seldom be cultured. Though Diabetes mellitus is very 
prevalent skin and soft tissue infections seldom get admitted in the medical 
wards, this may be the reason skin and soft tissue infections were rarely the 
cause of sepsis in the ward.  
Similar to the increased number of Gram-positive infections 
registered in recent years, the infections found in our patients were equally 
caused by Gram-positive and Gram-negative bacilli. The isolates and the 
percentage of the different microorganisms are as below .There was no 
correlation between the type of microorganisms and mortality, consistent 
with the earlier findings that all organisms whether gram-positive or 
negative were equipotent in producing sepsis. 
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Microbiological isolates were possible in only 54% of cases; one 
isolate from 39% and 2 from 15%.Candida was isolated from only one 
patient. The commonest isolate all samples included was CONS (22%), 
S.aureus (20%) and E.coli (14%) and Klebsiella (12%). One isolate of 
MRSA, S.pneumoniae and Enterococcus completed the gram positive 
spectrum. Pseudomonas, Acinetobacter, P.vulgaris, Citrobacter were the 
other gram negative isolates.  Though Widal test was positive in 10 cases 
only one was culture positive. Mycoplasma was isolated from one sample. 
Blood cultures were positive in 32% commonest isolates being 
CONS. Urine culture was positive in 30% cases the commonest isolate 
being E.coli. Sputum culture was positive in 35% and the commonest 
isolate was Klebsiella. E.coli was also the commonest isolate from all the 
other cultures - ascitic, pleural and cerebrospinal fluid. Though not 
intended in the study it was noted that almost all the isolates were 
susceptible to conventional antimicrobials like Ciprofloxacin, Amikacin, 
Sulphonamides and Erythromycin. The MRSA isolate was susceptible to 
vancomycin. 
Among the cases 28 had tropical infections (Malaria, Enteric Fever, 
Dengue and Leptospirosis). Malaria and Enteric Fever with 10 cases each. 
5 of them had leptospiriosis and 3 had dengue. All of them fully recovered. 
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The relation between increased mortality and both the number of 
organ failures at diagnosis and the progression toward multiple organ 
failure in septic patients is well established. To document the number of 
organ failure at diagnosis the criteria from SOFA score was used.  Moreno 
et al. reported in 1999 that the there was a good correlation between organ 
failures and mortality. A Spanish multicentre study indicated that 
persistent organ failure is significantly associated with mortality. 
The predictors of the outcome were underlying Diabetes or 
Hypertension. The prevalence of Diabetes mellitus and hypertension were 
18.2% and 18.9% respectively similar to the last incidence in the study in 
NEJM analyzing sepsis between 1979 and 2000. Underlying comorbidities 
had a bearing in both determining the severity of illness and the mortality 
rate. When multi organ systems were affected the incidence of sepsis and 
the progression to higher stages were evident, the prognosis was also poor. 
No comobidities were present in 31 cases. CNS diseases were the 
commonest underlying cause followed by CVS, RS and HB system. 
Malignancy was present in only two patients. The percentage of severe 
manifestation of sepsis was higher with illness in CVS, GUrT, HB and 
CNS. Proportional mortality rates were higher for multi organ system co-
morbidities, malignancy, hematological diseases and cardiovascular 
comorbidities.  
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While analyzing the variables that were determining severity of 
sepsis and prognosis presentations with hypothermia (40%), leucopenia 
(25%), hyper-glycemia in the absence of Diabetes (28.6%), and acutely 
altered mental status (22.2%) had higher death rates, the same for the 
opposite entities were 15% with hyperthermia, 14.7% with leucocytosis, 
15.2% without hyperglycemia, 14.3% without altered mental status. 
Though the commonest presentations in sepsis were fever, tachycardia, 
tachypnea, and leucocytosis, cases were admitted with hypothermia and 
leucopenia. Such presentations represent poorer response from the patient 
to an infection and hence place them under high risk of succumbing to the 
illness.  
The category of severity at the time of presentation also had a 
bearing on the outcome. The less severe SIRS/Sepsis group had a death 
rate of 9.2%, while the rate was 18.6% for severe sepsis; it rose to 29.2% 
in the septic shock group. 
Underlying co-morbid illnesses in multiple organ systems (60%), 
with underlying malignancy (50%), hematological diseases (40%), and 
CVS diseases (31%) had higher death rates. Those without any diseases, 
CNS diseases, HB diseases fared better. Though respiratory tract was the 
commonest site of infection an underlying RS disease did not have a 
poorer outcome. Poorer outcomes were noticed if the source of infection 
was the respiratory tract and the genitourinary tract. Outcomes were better 
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with Tropical infections, CNS, Skin infections, GIT infections (all 
recovered).  
 Analyzing the physiological variables and the severity of illness it 
was noticed that the mean levels of systolic BP, Diastolic BP, Platelet 
counts, PaO2/FiO2 ratios, pH levels were lower in the septic shock group 
than the SIRS/Sepsis group, while the mean levels of APACHE-II scores, 
Lactate levels, Urea and creatinine levels, Total bilirubin and SGPT levels 
were higher in the septic shock group compared to SIRS/Sepsis group.  
 
 
 
 
. 
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CONCLUSIONS 
 The incidence of sepsis remains high in our population. Male 
patients were more in proportion. Higher age group had more severe 
disease and mortality rates. Females had higher mortality.  
 The severity at presentation determines the prognosis. 
 Underlying SHT, DM, and multi-system comorbidities at 
presentation have poorer outcomes. 
 Hypothermia, Leucopenia, Hyperglycemia, altered mental status 
place the patients at poorer prognosis. 
 Higher Creatinnine, Urea, Bilirubin, SGPT, Lactate, APACHE-II 
scores Lower pH (acidosis), platelet counts, Mean SBP and DBP, 
PaO2/FiO2 ratios were seen in more severe disease and portended 
poorer outcomes. 
 Respiratory tract remains the commonest source of infections. 
 Both gram positive and gram negative organisms have equal 
incidence but do not have a bearing on the outcome. 
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 Sepsis syndrome is common in academic hospitals, although the 
overall rates vary considerably with the patient population.
 
A 
substantial fraction of cases occur outside ICUs. An 
understanding
 
of the hospital wide epidemiology of sepsis syndrome 
is vital
 
for rational planning and treatment of hospitalized 
patients
 
with sepsis syndrome, especially as new and expensive 
therapeutic
 
agents become available 
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LIMITATIONS OF THE STUDY 
This study has some limitations.  
First, although this is the first attempt of specifically designed 
epidemiological study of sepsis spectra in our medical wards the sample 
size was small and hence it is difficult to extrapolate the results to the 
general population.  
Secondly, though there were differences between the different 
subgroups / outcome groups with regard to the different variables studied, 
a statistical significance could not be established in some of the variables. 
Nevertheless, this study can serve as a reference for future studies about 
these variables.  
Third, the effect of seasonal variation on the incidence of sepsis is 
well known. [31].  The study period comprised of only summer-autumn, its 
effects are difficult to measure. The higher incidence of tropical infections 
may be because of this seasonal preference. 
Thus, our results can also be useful as a reference for future studies 
about the impact of these measures when introduced on the outcome of 
patients with sepsis admitted to the medical wards in our setting.  
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LIST OF ABBREVIATIONS 
1. AcMenEn : Acute meningoencephalitis  
2. AGE  : Acute gastroenteritis 
3. APACHE : Acute physiology and chronic health  evaluation  
 
4. APTT : Activated partial thromboplastin time 
5. ARDS  : Acute respiratory distress syndrome 
6. ASD  : Atrial septal defect 
7. Asp Pn : Aspiration pneumonia 
8. BA  : Bronchial asthma 
9. BrPn  : Bronchopneumonia 
10. Ca Cx : Cancer cervix 
11. Ca Eso : Cancer esophagus 
12. CABpn : Community acquired Bronchopneumonia 
13. CAD  : Coronary artery disease 
14. Cbl Mal : Cerebral malaria 
15. CD  : Cluster of Differentiation 
16. CHF  : Congestive heart failure 
17. ChrBritis : Chronic Bronchitis  
18. CIDP  : Chronic inflammatory demyelinating  
polyneuropathy 
 
19. CKD  : Chronic kidney disease 
20. CML  : Chronic myeloid leukemia 
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21. CNS  : Central Nervous system 
22. Comm : Commensals 
23. CONS : Coagulase negative staphylococcus 
24. COPD : Chronic obstructive pulmonary disease 
25. CRP  : C-reactive protein 
26. CSOM : Chronic suppurative otitis media 
27. CT  : Computed tomography 
28. CVA  : Cerebrovascular accident 
29. CVS  : Cardiovascular system 
30. DCLD : Decompensated Liver Disease 
31. DCMP : Dilated cardiomyopathy 
32. Disch  : Discharge 
33. DKA  : Diabetic ketoacidosis  
34. DMT1/2 : Diabetes mellitus type 1/2  
35. E.Coli : Escherechia coli 
36. EHPVO : Extrahepatic portal vein obstruction 
37. Ent Fev : Enteric fever 
38. GBS  : Guillaine barre syndrome 
39. GCS  : Glasgow coma scale 
40. GCSF : Granulocyte colony–stimulating factor   
41. GIT  : Gastrointestinal system 
42. GUrT : Genitourinary system 
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43. HB  : Hepatobiliary system 
44. HE  : Hepatic Encephalopathy 
45. HELLP : Hemolysis, Elevated liver enzymes, Low 
platelets  
46. Hem  : Hematological 
47. HIV  : Human immunodeficiency virus  
48. HMGB1 : High-mobility group box1 
49. HyKPP : Hypokalemic periodic paralysis  
50. ICU  : Intensive Care Unit 
51. IFN   : Interferon       
52. IL  : Interleukin  
53. ILD  : Interstitial  lung disease 
54. ImmSup : Immunosuppression 
55. ITU  : Intensive Trauma Unit 
56. Klebs  : Klebsiella 
57. Lepto : Leptospirosis 
58. LPS   : Lipopolysaccharide 
59. M.plasma : Mycoplasma 
60. Malig  : Malignancy 
61. MIF   : Macrophage
 
migration inhibitory factor 
62. MODS : Multiple organ dysfunction syndrome 
63. MOS  : Multiple organ systems 
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64. MRSA : Methicillin resistant staph aureus 
65. N  : No 
66. NG  : No Growth 
67. P.vulg : Proteus vulgaris  
68. PAF  : Platelet activating factor 
69. PCT  : Procalcitonin 
70. PHT  : Portal hypertension 
71. PID  : Pelvic inflammatory disease 
72. PpCMP : Postpartum cardiomyopathy 
73. PTb   : Pulmonary tuberculosis 
74. PyNeph : Pyelonephritis  
75. RA  : Rheumatoid arthritis 
76. rhAPC : Recombinant Human Activated Protein C 
77. RHD  : Rheumatic heart disease 
78. RS  : Respiratory system 
79. S.aureus : Staphylococcus aureus 
80. S.pneum : Streptococcus pneumonia 
81. SBP  : Spontaneous bacterial peritonitis  
82. SD  : Standard deviation 
83. Seiz Dis : Seizure disorder 
84. Sev Sep : Severe sepsis 
85. SHT  : Systemic hypertension 
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86. SIRS  : Systemic inflammatory response syndrome  
87. SLE  : Systemic lupus erythematosus 
88. SS  : Septic shock syndrome 
89. TLR  : Toll-like receptors
 
 
90. TNF-  : Tumor
 
necrosis factor  
91. UGIB : Upper gastrointestinal bleed 
92. UTI  : Urinary tract infection 
93. WBC  : White blood cell count 
94. Y  : Yes 
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PROFORMA 
Name                                                  : 
Age                                                     : 
Gender                                                :  
Complete Diagnosis                           :  
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Vitals :  
Temp Pulse BP Resp Rate JVP Hydn 
Status 
      
 
CBC  RFT  LFT  ABG  
TC  Urea  Bilirubin(T)  pH  
DC  Creatinine  Bilirubin(D)  pCO2  
ESR  Sodium  Bilirubin(I)   HCO3-  
Hb%  Potassium  SGOT  pO2  
PCV  Sugar  SGPT  BE  
Plat  BT  SAP  AG  
Bld Gp  PT/INR  TP  Lactate  
Rh 
Type 
 aPTT  Alb/Glob    
 
 
 
 
 
 
 
82 
 
MicroBiological Examination  :  As Appropriate for clinical setting 
Blood 
Culture/Sensitivity 
 
Urine 
Culture/Sensitivity 
 
CSF  
Culture/Sensitivity 
 
Wound 
Culture/Sensitivity 
 
Sputum 
Culture/Sensitivity 
 
Others 
Culture/Sensitivity 
 
 
Smear MP/MF  Lepto MSAT  
Dengue IgM/IgG  Widal Test  
 
Peripheral Smear  
Chest X-ray   
USG –Abd  
ECG  
ECHO  
 
 
 
Treatment                                   :  
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Fluid Therapy  (Total )  
 
Crystalloids  
Colloids  
Blood Products  
 
Vasopressors/Inotropic Therapy  (Total )  
 
Isoproterenol   
Dopamine   
Epinephrine   
Norepinephrine   
Dobutamine   
 
Anti-Biotics Used/Dose / No.of Dys  
   
   
   
   
 
 
Steroids  Yes /  No  Dose  : 
Mechanical Ventilation   
Glucose Control   
Renal Replacement   
Bicarbonate Therapy   
Deep Vein Thrombosis Prophylaxis   
Stress Ulcer Prophylaxis   
Sedation, Analgesia, and NM Blockade   
Surgical Interventions   
 
Outcome                                     :  
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
1 Velu 34 M Y N Y Y Y N N N 4 5 6 15 101.4 114 110 78 23 
2 Vijayaragavalu 44 M Y N Y Y Y N N Y 4 4 5 13 101.4 104 100 70 29 
3 Kumaresan 17 M Y N Y Y Y N N Y 2 3 6 11 101.2 98 120 82 29 
4 Saraswathy 54 F Y N Y Y Y N N Y 2 2 5 9 101.4 112 84 52 28 
5 Mekala 26 F Y N Y Y Y N N N 4 5 6 15 102.4 98 110 70 22 
6 Kumar 38 M Y N Y Y Y N N N 3 4 5 12 101.4 116 110 80 26 
7 Saraswathy 57 F Y N Y Y Y N N N 4 5 5 14 101 98 120 80 27 
8 Vijayakumar 49 M Y N Y Y Y N N N 4 5 6 15 101.4 98 100 74 23 
9 Ramesh  30 M Y N Y Y Y N N N 3 4 6 13 101.4 100 106 80 21 
10 Arpudhasagayaraj 30 M Y N Y Y Y N N N 3 4 5 12 101.4 118 110 76 30 
11 Amaravathy 40 F Y N Y Y Y N Y Y 2 2 4 8 101.4 110 120 68 28 
12 Soundary 43 F Y N Y Y Y N N Y 3 3 5 11 103 126 100 70 21 
13 Shanthi 38 F Y N Y Y Y N N N 4 5 6 15 101.4 102 94 72 22 
14 Thyagarajan 40 M Y N Y Y Y N N N 4 5 6 15 102.6 120 80 60 27 
15 Gurusamy 55 M Y N Y Y Y N N N 4 4 5 13 102.6 120 140 90 23 
16 Mohan 58 M Y N Y Y Y N N Y 2 3 5 10 95.8 100 102 72 24 
17 Balan 30 M N Y Y Y Y N N Y 2 2 4 8 96.6 92 90 60 23 
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18 Gunalan 54 M Y N Y Y Y N N N 4 5 6 15 102.6 102 110 70 24 
19 Valliammal 44 F Y N Y Y Y N N Y 2 3 5 10 95.8 110 150 92 23 
20 Rajendran 58 M Y N Y Y Y N N N 4 4 5 13 102 120 160 90 24 
21 Ravi 44 M Y N Y Y Y N Y N 4 5 6 15 101.8 112 140 88 23 
22 Selvaray 62 M N Y Y Y Y N N N 4 5 6 15 102 106 118 78 24 
23 Jayalakshmi 70 F Y N Y Y N Y N Y 2 4 5 11 96.2 96 130 80 23 
24 Chengammal 34 F Y N Y Y Y N Y N 3 5 6 14 102.2 102 100 50 27 
25 Venkatasubbiah 45 M Y N Y Y Y N N N 4 5 6 15 102.2 118 100 60 23 
26 Jayanthi 53 F Y N Y Y Y N N N 3 3 5 11 101 108 120 40 29 
27 Latha 30 F Y N Y Y Y N N N 2 2 4 8 102.4 108 70 56 28 
28 Moorthy 27 M Y N Y Y Y N N N 4 5 6 15 101 102 100 70 24 
29 Nagaraj 32 M Y N Y Y N Y N N 4 5 6 15 103 116 110 74 26 
30 Subbiah 23 M Y N Y Y Y N N Y 2 2 3 7 101.4 104 78 54 28 
31 Vasanth 28 M Y N Y Y N Y N N 4 5 6 15 101.4 116 106 76 30 
32 Vijaya 53 F Y N Y Y Y N N N 4 5 6 15 101.4 104 160 90 22 
33 Chokkammal 51 F Y N Y Y Y N N N 3 4 5 12 104 108 150 94 28 
34 Amul 21 F Y N Y Y Y N N N 4 5 6 15 101.4 122 120 80 28 
35 Sathya 17 F N Y Y Y Y N N N 3 4 6 13 101.6 96 70 48 21 
36 Kondammal 63 F Y N Y Y Y N N N 4 5 6 15 101.4 104 112 76 24 
37 Pappi 43 F Y N Y Y Y N N N 4 5 6 15 101.4 100 118 76 30 
38 Raja 17 M Y N Y Y Y N N Y 2 3 5 10 101.4 112 110 80 27 
39 Ragini 16 F Y N Y Y N Y N N 4 5 6 15 101.4 108 108 78 21 
40 Devaki 48 F Y N Y Y Y N N N 4 5 6 15 102.6 118 150 90 26 
41 Saravanan 24 M Y N Y Y Y N N N 4 5 6 15 101.4 106 120 74 27 
42 Ashok 18 M Y N Y Y Y N N N 4 5 6 15 102.4 118 110 76 21 
43 Naseer ahmed 54 M Y N Y Y Y N N N 4 5 6 15 101.4 108 170 100 25 
44 Devi 21 F Y N Y Y Y N N N 3 4 6 13 101.4 106 100 70 30 
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45 Masthan 78 M Y N Y Y Y N N N 3 3 5 11 101.4 112 120 80 22 
46 Rajarajan 40 M Y N Y Y N Y N N 3 5 6 14 101.6 110 110 70 22 
47 Thangammal 52 F Y N Y Y Y N N N 4 5 6 15 101.4 110 120 76 27 
48 Anjeeswaran 53 M Y N Y Y N Y N Y 2 2 4 8 102.2 104 80 50 26 
49 Sundaresan 16 M Y N Y Y Y N N N 3 4 6 13 103 108 110 70 29 
50 Lalitha 39 F Y N Y Y Y N N N 4 5 6 15 102 94 102 70 25 
51 Kondiah 70 M Y N Y Y Y N N Y 2 2 4 8 101.4 114 150 88 24 
52 Ramachandran 70 M Y N Y Y Y N N N 3 4 5 12 102.2 118 200 120 24 
53 Muralidaran 20 M Y N Y Y Y N N N 4 5 6 15 102.4 120 110 70 24 
54 Revathi 70 F Y N Y Y Y N N Y  2 2  4  8 96 100 80 40 28 
55 Rajeswari 38 F Y N Y Y Y N N N  4 5  6  15 101.4 104 110 70 27 
56 Anand 15 M Y N Y Y Y N N Y  3 3  4  10 101.4 98 110 80 23 
57 Senthilkumar 25 M Y N Y Y Y N N Y 3 3 5 11 101 100 100 70 24 
58 Dhanammal 64 F Y N Y Y Y N N N 4 5 6 15 101.4 96 108 78 28 
59 Beevi 52 F Y N Y Y Y N N N 4 5 6 15 101.4 114 110 80 27 
60 Venakatramanamma 24 M Y N Y Y N Y N N 3 5 6 14 102.2 100 120 80 21 
61 Jeganathan 18 M Y N Y Y N Y N N 4 5 6 15 101.6 96 110 78 27 
62 Kuttiammal 55 M Y N Y Y Y N N N 4 5 6 15 101.4 102 160 90 30 
63 Meenatchi 21 F Y N Y Y Y N N N 3 3 5 11 102 94 80 80 21 
64 Thulasiammal 60 F Y N Y Y Y N N N 3 5 6 14 101.6 112 80 80 26 
65 Muniyammal 60 F Y N Y Y Y N Y N 4 5 6 15 101.4 106 150 96 20 
66 Shanthi 50 F Y N Y Y Y N N N 4 5 6 15 102 106 140 90 21 
67 Viji 19 F Y N Y Y Y N N N 4 5 6 15 101.4 122 180 90 29 
68 Polammal 65 F N Y Y Y Y N Y N 2 2 4 8 101.4 116 70 50 27 
69 Shanthi 35 F Y N Y Y N Y N N 4 5 6 15 102 104 100 68 27 
70 Premavathy 57 F Y N Y Y Y N N Y 1 1 1 3 96 94 84 50 25 
71 Bhavanakumar 51 M Y N Y Y N Y N Y 2 2 4 8 96.4 100 130 40 28 
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72 Nirmala 55 F Y N Y Y N Y N N 3 3 5 11 101.8 96 160 94 20 
73 Thangadurai 56 M Y N Y Y Y N N N 3 5 6 14 101.4 104 170 96 23 
74 Shanmughi 20 F Y N Y Y Y N N N 4 5 6 15 101.8 96 120 70 25 
75 Parimala 25 F Y N Y Y Y N N N 4 5 6 15 101.6 96 116 76 20 
76 Sakunthala 65 F Y N Y Y Y N N N 4 5 6 15 102.8 108 170 90 25 
77 Mohan 45 M Y N Y Y Y N N N 3 4 6 13 102 120 120 80 28 
78 Selvi 40 F Y N Y Y Y N N N 4 5 6 15 102 102 102 70 25 
79 Subramani 36 M Y N Y Y Y N N N 4 4 5 13 101.4 100 100 66 22 
80 Koottees 23 M Y N Y Y Y N N N 4 5 6 15 102.6 110 108 70 24 
81 Loganathan 55 M Y N Y Y Y N N N 2 3 5 10 101.4 104 110 68 22 
82 Kasi 40 M Y N Y Y Y N N N 3 5 5 13 102.4 108 120 80 28 
83 Sudharshan 21 M Y N Y Y Y N N N 4 5 1 10 102 102 110 80 29 
84 Kishore 15 M Y N Y Y Y N N Y 2 2 4 8 96 90 120 80 24 
85 Rajasekaran 67 M Y N Y Y Y N N N 4 5 6 15 101.8 116 100 78 29 
86 Indirani 60 F Y N Y Y Y N Y N 4 5 6 15 101.6 106 110 80 24 
87 Arumugam 45 M Y N Y Y Y N N N 3 5 6 14 101.4 118 116 76 21 
88 Arumugam 41 M Y N Y Y Y N N N 4 1 5 10 102 98 70 50 23 
89 Amaravalli 30 F Y N Y Y Y N N N 4 5 6 15 101.8 106 100 60 26 
90 Loganathan 21 M Y N Y Y Y N N N 4 5 6 15 101.4 92 110 70 27 
91 Hanifa 66 M Y N Y Y Y N N N 4 5 6 15 101.4 102 130 50 21 
92 Dhanapriya 87 M N Y Y Y Y N N Y 2 2 5 9 96.2 116 70 50 20 
93 Madan 18 M Y N Y Y Y N N N 4 5 6 15 101.4 110 100 70 21 
94 Govindaraj 80 M Y N Y Y N Y N Y 2 2 4 8 101.6 108 110 80 29 
95 Pushpammal 50 F Y N Y Y Y N N N 4 5 6 15 101.6 108 120 80 24 
96 Lakshmi 55 F Y N Y Y Y N N N 4 5 6 15 102 120 110 80 31 
97 Gunaselvi 58 F Y N Y Y Y N N N 4  5  6  15 101.4 118 106 76 26 
98 Haribabu 16 M Y N Y Y Y N N N 4 5 6 15 101.4 100 110 78 28 
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99 Ayyasamy 64 M Y N Y Y Y N N N 4 5 6 15 101.8 110 100 70 24 
100 Janakiraman 24 M Y N Y Y Y N N N 4 5 6 15 101.4 116 80 50 28 
101 Kaliyuganga 51 F Y N Y Y Y N N N 4 5 6 15 101.8 98 120 80 27 
102 Pandi 47 M Y N Y Y Y N N N 4 5 6 15 101.4 110 110 76 30 
103 Mallika 43 F Y N Y Y Y N N N 4 5 6 15 101.6 94 120 80 29 
104 Anjalai 15 F Y N Y Y Y N N N 4 5 6 15 102.4 108 110 70 29 
105 Manjula 53 F Y N Y Y Y N N N 4 5 6 15 101.4 114 160 90 21 
106 Eswari 44 F Y N Y Y Y N N N 4 5 6 15 101.4 96 110 70 29 
107 Chandrasekaran 40 M Y N Y Y Y N N N 4 5 6 15 101.4 110 120 70 32 
108 Muthalagan 53 M Y N Y Y Y N N N 4 5 6 15 102 122 110 78 27 
109 Karunakaran 50 M Y N Y Y Y N N N 3 4 6 13 101.4 112 100 70 27 
110 Kuppammal 60 F Y N Y Y N Y Y N 4 5 6 15 101.4 98 190 100 21 
111 Sathya 34 M Y N Y Y Y N N N 4 5 6 15 101.4 96 100 80 21 
112 Kasiammal 76 F Y N Y Y Y N N N 4 5 6 15 101.8 110 102 76 27 
113 Gowri 38 F Y N Y Y Y N N N 4 5 6 15 101 100 110 80 27 
114 Elumalai 48 M Y N Y Y N Y N Y 2 2 4 8 101.4 112 88 58 20 
115 Ponnusamy 53 M Y N Y Y Y N N N 4 5 6 15 101.4 114 180 102 26 
116 Ruby 35 M Y N Y Y Y N N Y 2 2 5 9 101.4 108 96 66 27 
117 Harishankar 15 M Y N Y Y Y N N N 4 5 6 15 101.8 110 112 87 26 
118 Amudha 48 F Y N Y Y Y N N N 4 5 6 15 102.4 96 126 80 22 
119 Pushpa 36 F Y N Y Y Y N N N 4 5 6 15 101 98 110 80 29 
120 Vignesh 18 M Y N Y Y Y N N N 3 3 5 11 101.4 116 120 80 23 
121 Arun 23 M Y N Y Y Y N N N 4 5 6 15 102 126 110 70 27 
122 Rubin 15 M Y N Y Y Y N N N 4 5 6 15 102 124 100 76 22 
123 Sivanathan 29 M Y N Y Y Y N N N 4 5 6 15 102.8 98 88 56 18 
124 Prakash 31 M Y N Y Y Y N N N 2 4 5 11 101.4 104 96 70 22 
125 Abdul raheem 60 M Y N Y Y N Y N Y 2 2 4 8 102.6 122 80 50 26 
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126 Sekar 47 M Y N Y Y Y N N N 4 5 6 15 101.4 102 100 70 28 
127 Senthil 27 M Y N Y Y N Y N N 3 4 6 13 101.4 112 80 64 22 
128 Vinoth 19 M Y N Y Y Y N N Y 2 2 4 8 96.4 96 60 40 26 
129 Preethishanthi 22 F Y N Y Y Y N N Y 3 1 5 9 101 98 106 72 20 
130 Ramachandran 49 M Y N Y Y Y N N N 4 5 6 15 102.8 100 100 70 22 
131 Ravanappa 47 M Y N Y Y Y N N Y 2 1 4 7 102.4 102 190 94 28 
132 Thangappan 55 M Y N Y Y Y N N N 4 5 6 15 103 113 140 80 31 
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22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 
36.3 11600 66/28/6 31 11.6 2.68 31 1.0 137 4.4 98 1.0 40 43 6.1 3.4 7.34 21.0 94.0 46.0 24.0 447.6 2.0 0 30 
31.3 12000 66/28/6 52 10.0 0.94 78 1.6 129 4.4 80 4.9 86 67 5.6 2.3 7.29 40.0 85.1 37.0 17.5 212.8 4.2 4 35 
35.7 12600 70/26/4 25 11.4 2.66 40 0.8 143 4.5 96 0.9 49 45 6.7 4.0 7.50 21.0 92.4 32.0 26.0 440.0 3.0 0 30 
31.3 12800 64/28/8 30 10.0 1.10 69 1.8 130 4.4 129 3.3 98 40 6.2 3.0 7.24 40.0 81.1 28.0 12.0 202.8 4.6 3 38 
35.2 12080 82/15/3 38 11.3 2.09 34 0.7 131 3.7 112 1.2 46 93 6.7 3.2 7.41 21.0 94.3 38.0 23.2 449.0 2.4 0 24 
41.3 12160 70/23/7 58 13.2 1.92 37 1.0 129 3.0 117 1.0 51 92 6.4 3.6 7.49 21.0 94.0 28.0 22.0 447.6 2.3 0 29 
32.6 13400 66/28/6 78 10.4 1.37 44 1.1 135 3.1 124 1.2 56 77 6.0 3.3 7.35 21.0 92.0 48.0 25.8 438.1 2.0 0 28 
30.7 12184 61/35/4 45 9.8 2.44 36 1.2 139 3.5 76 0.9 38 38 6.1 3.0 7.39 21.0 91.0 39.0 23.0 433.3 1.8 0 23 
35.2 11880 61/35/4 60 11.2 1.57 39 0.9 128 2.8 88 0.8 41 80 6.0 3.3 7.29 21.0 92.0 60.0 28.0 438.1 2.9 0 29 
35.1 11840 65/28/7 76 11.2 1.60 78 2.3 132 4.0 110 1.1 38 54 6.3 2.3 7.03 40.0 87.0 45.0 14.0 217.5 4.3 3 38 
35.2 11960 61/32/7 45 11.2 1.20 114 3.6 133 3.0 126 1.2 50 72 5.8 2.8 7.15 40.0 94.0 54.0 20.0 235.0 4.4 2 34 
28.2 33800 72/22/6 21 9.0 0.90 43 0.8 130 3.0 94 0.9 41 82 6.1 2.6 7.05 40.0 91.2 39.7 12.7 227.9 6.1 3 44 
32.6 12120 60/34/6 54 10.4 1.04 41 0.9 129 3.7 102 1.1 64 70 6.3 3.3 7.33 21.0 95.0 44.6 23.0 452.4 1.8 0 25 
35.2 11520 64/28/8 45 11.2 1.54 73 1.6 139 4.3 66 1.9 64 49 6.2 2.4 7.06 40.0 86.0 43.0 13.9 215.0 4.5 2 40 
30.7 12200 61/35/4 25 9.8 1.02 92 2.9 134 3.7 107 1.7 87 48 6.3 2.3 7.35 40.0 84.0 26.0 14.0 210.0 5.7 3 36 
37.6 13800 74/22/4 49 12.0 1.91 46 0.8 146 3.8 120 1.0 36 46 6.3 3.2 7.49 21.0 90.0 34.0 26.0 428.6 3.4 0 37 
35.1 11800 64/28/8 70 11.2 1.74 54 1.6 133 4.2 97 1.2 44 54 7.7 4.7 7.29 40.0 87.3 34.0 16.0 218.2 4.7 2 34 
91 
 
40.7 13000 69/26/5 39 13.0 2.30 44 1.2 132 4.1 103 1.1 55 69 6.8 3.4 7.33 21.0 94.0 45.0 23.0 447.6 2.0 0 28 
40.7 11960 68/26/6 77 13.0 1.19 39 1.1 136 3.6 111 0.9 70 100 5.6 2.6 7.11 21.0 91.5 52.0 18.0 435.6 2.3 0 40 
36.3 14000 66/23/11 78 11.6 0.98 98 3.1 129 4.1 102 2.2 66 48 6.9 3.8 7.07 40.0 84.0 49.0 16.0 210.0 6.0 4 45 
40.7 12256 74/22/4 38 13.0 1.04 36 0.9 145 3.3 132 0.9 32 56 6.4 3.1 7.31 21.0 89.0 45.3 22.0 423.8 1.9 0 29 
31.3 12184 65/28/7 39 10.0 2.27 47 1.0 135 3.2 112 0.7 42 43 6.2 3.5 7.39 21.0 97.0 41.0 24.0 461.9 1.8 0 28 
30.7 2900 66/23/11 26 9.8 1.02 47 0.8 128 3.4 136 0.8 55 84 5.3 3.2 7.36 21.0 88.9 36.0 19.8 423.3 2.0 0 36 
34.4 11560 74/22/4 58 11.0 0.95 43 1.1 131 4.4 142 3.3 134 81 6.0 3.0 7.13 40.0 90.0 51.0 18.3 225.0 6.1 4 30 
35.0 12112 76/22/2 63 11.2 1.85 33 1.2 134 3.6 92 2.7 78 34 6.6 2.6 7.33 21.0 91.5 43.2 22.1 435.7 2.9 0 33 
32.2 11400 70/23/7 78 10.3 0.80 90 4.3 135 3.6 157 4.4 97 61 6.1 2.9 7.14 40.0 97.0 43.7 15.8 242.5 6.1 4 43 
22.5 11760 62/32/6 49 7.2 0.60 74 2.9 137 4.3 111 5.4 214 143 5.1 2.9 7.43 40.0 89.0 37.0 23.9 222.5 5.3 4 37 
43.8 12040 61/32/7 79 14.0 0.70 62 2.0 133 3.2 86 1.0 36 83 6.1 3.8 7.31 40.0 93.0 45.8 22.4 232.5 4.3 4 29 
35.1 2160 80/13/7 57 11.2 1.87 43 0.9 136 3.5 112 0.6 41 99 5.3 3.0 7.40 21.0 91.0 36.9 22.3 433.3 3.1 0 29 
33.2 12400 66/28/6 69 10.6 1.09 77 2.3 133 4.4 107 2.5 146 51 6.8 3.3 7.25 40.0 79.6 37.0 16.0 199.0 4.9 4 37 
35.2 3100 69/26/5 65 11.2 1.02 34 0.6 136 4.5 94 0.8 37 43 6.4 2.9 7.27 21.0 93.0 50.0 22.6 442.9 2.9 0 28 
38.8 12200 60/34/6 77 12.4 2.87 59 1.6 144 3.9 146 0.7 40 46 5.5 2.7 7.36 21.0 95.0 45.0 24.8 452.4 1.9 0 32 
33.9 16000 61/35/4 60 10.8 1.48 64 1.7 140 3.9 130 1.6 68 85 5.9 3.0 7.18 40.0 86.3 49.0 19.0 215.8 6.2 2 37 
31.3 12400 61/35/4 68 10.0 2.02 47 0.9 130 2.9 106 1.1 53 100 5.5 3.2 7.35 21.0 92.3 41.7 22.4 439.5 3.7 0 28 
33.2 12800 64/32/4 46 10.6 0.77 79 1.9 135 3.0 162 0.8 66 96 6.8 4.2 7.05 40.0 95.3 51.0 16.2 238.1 6.1 2 33 
33.2 12192 64/28/8 58 10.6 1.53 83 2.9 132 3.5 104 0.9 61 79 8.0 4.8 7.32 40.0 86.0 32.0 16.0 215.0 5.7 3 31 
31.3 12080 70/27/3 29 10.0 1.37 54 0.8 142 3.6 95 1.0 37 85 5.8 3.2 7.36 21.0 93.5 42.4 23.0 445.2 2.3 0 24 
35.1 13000 70/23/7 26 11.2 0.77 70 1.6 136 3.8 118 1.9 120 62 6.4 3.4 7.08 40.0 94.1 45.0 14.9 235.3 6.5 2 37 
27.5 3200 70/27/3 74 8.8 1.32 43 0.8 146 4.2 134 0.9 56 50 6.7 3.6 7.37 21.0 93.0 38.0 21.0 442.9 2.0 0 25 
34.9 12160 64/28/8 61 11.1 1.12 134 4.2 131 4.0 114 1.3 88 38 5.1 2.5 7.28 40.0 79.0 28.0 13.0 197.5 4.2 3 37 
32.2 12280 66/23/11 45 10.3 1.94 43 1.1 146 3.7 98 0.8 48 74 6.4 3.5 7.33 21.0 93.0 45.0 23.0 442.9 2.0 0 24 
40.1 13200 60/34/6 30 12.8 1.31 47 0.7 132 3.5 112 1.0 70 77 6.4 4.0 7.37 21.0 91.0 38.0 21.0 433.3 2.1 0 26 
40.7 13200 74/22/4 17 13.0 1.45 54 1.0 137 4.3 120 0.9 67 62 5.6 2.9 7.33 21.0 94.6 41.1 21.1 450.5 2.0 0 26 
35.7 12600 65/28/7 66 11.4 0.91 53 1.4 137 3.0 103 2.5 135 75 5.5 3.0 7.26 40.0 91.0 46.0 20.3 227.5 4.1 3 29 
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40.1 14000 74/22/4 42 12.8 1.35 60 1.3 144 4.7 88 1.0 69 96 6.0 2.9 7.21 40.0 95.3 57.3 23.3 238.3 4.9 2 38 
27.9 3680 49/46/5 22 8.9 1.17 40 1.1 140 4.6 106 0.7 42 74 6.7 4.1 7.40 21.0 93.1 40.1 24.0 443.3 3.0 0 29 
35.1 11480 62/32/6 30 11.2 2.28 47 0.9 137 4.0 98 0.9 71 50 7.8 3.5 7.23 21.0 89.9 49.7 21.0 428.1 2.1 0 31 
30.7 3300 62/32/6 36 9.8 2.85 80 2.2 128 3.8 200 2.8 133 47 6.1 4.0 7.14 40.0 94.9 39.5 14.4 237.3 5.9 4 43 
38.5 12200 81/13/6 60 12.3 1.75 72 1.2 129 4.3 100 0.8 49 54 6.3 3.0 7.27 40.0 95.4 31.0 14.0 238.6 5.6 2 33 
35.2 12000 82/15/3 16 11.3 1.20 45 0.9 134 3.9 108 1.2 45 37 6.9 3.4 7.32 21.0 93.6 41.8 21.0 445.7 1.9 0 27 
33.9 13200 76/22/2 22 10.8 1.13 56 0.9 134 3.8 167 0.7 41 95 6.8 3.5 7.42 21.0 93.0 37.5 23.5 442.9 1.8 0 37 
31.3 13400 72/23/5 46 10.0 1.18 77 3.9 144 4.3 97 0.8 53 60 5.8 3.2 7.38 21.0 91.3 37.9 21.8 434.8 3.0 0 38 
36.3 13200 69/26/5 44 11.6 1.58 40 0.9 143 3.8 94 0.9 61 50 5.4 3.1 7.28 21.0 93.8 38.0 17.4 446.7 1.2 0 28 
33.2 13600 80/13/7 76 10.6 2.26 65 3.9 134 3.3 122 0.4 42 91 6.1 4.3 7.40 40.0 91.9 41.3 24.8 229.7 3.4 2 50 
35.3 12080 62/32/6 79 11.3 0.99 73 3.8 138 4.2 91 2.2 57 46 6.4 4.6 7.05 40.0 84.4 62.5 19.9 211.0 5.7 3 47 
37.6 12200 72/23/5 71 12.0 1.53 51 3.9 129 4.2 104 4.9 47 53 7.4 4.3 7.17 40.0 71.9 61.1 23.4 179.8 3.8 3 47 
32.6 12160 62/32/6 23 10.4 1.21 46 1.1 133 4.3 98 1.6 50 39 6.2 3.4 7.41 40.0 91.9 42.0 26.0 229.8 5.7 2 27 
35.1 12200 62/32/6 26 11.2 1.64 33 0.8 138 3.1 122 1.1 65 59 6.5 3.0 7.20 21.0 94.0 42.0 16.7 447.6 1.5 0 31 
32.9 11440 64/32/4 54 10.5 1.53 45 1.2 142 4.0 117 0.7 58 93 6.7 3.7 7.19 21.0 92.4 49.0 19.3 440.0 2.0 0 31 
38.8 2240 76/22/2 73 12.4 0.92 62 1.3 138 4.5 99 2.5 63 71 5.0 2.7 7.25 40.0 88.6 47.0 20.5 221.5 4.3 2 27 
32.2 3400 62/32/6 43 10.3 1.78 40 1.1 129 3.8 95 1.4 65 66 5.7 3.2 7.36 21.0 92.0 41.0 22.6 438.1 2.4 0 27 
35.0 12400 65/28/7 35 11.2 0.77 38 1.1 133 3.4 94 1.3 48 59 6.9 4.1 7.27 21.0 93.2 49.3 22.3 443.8 4.4 2 30 
27.5 33,400 64/28/8 59 8.8 0.64 118 3.6 132 4.0 121 2.3 59 77 7.0 4.0 7.29 40.0 92.8 35.0 16.5 231.9 5.6 3 41 
31.0 13200 72/23/5 28 9.9 1.33 34 0.9 138 3.3 105 2.6 73 56 6.3 3.3 7.26 40.0 86.9 42.6 19.0 217.3 5.8 2 34 
35.7 12200 72/23/5 17 11.4 1.03 58 2.5 135 3.3 196 4.2 107 58 6.4 3.0 7.23 21.0 85.5 49.3 20.7 407.1 5.2 3 38 
35.7 12200 64/28/8 16 11.4 2.11 45 0.7 132 4.4 97 0.7 33 67 6.0 3.3 7.33 21.0 92.4 42.0 21.3 440.0 1.9 0 26 
32.6 14000 61/32/7 37 10.4 1.74 68 1.7 136 3.4 104 3.0 62 65 5.5 2.4 7.06 21.0 94.1 53.0 17.1 448.0 5.5 1 33 
32.2 14300 69/23/8 76 10.3 1.49 123 3.6 142 3.5 142 3.1 63 78 6.6 4.9 7.30 40.0 84.0 58.1 13.1 210.0 5.5 3 44 
30.7 1800 81/13/6 52 9.8 1.79 54 0.8 141 4.2 112 0.9 78 48 6.6 3.1 7.39 21.0 95.2 40.8 24.2 453.3 1.8 0 25 
34.9 13600 68/26/6 62 11.1 0.94 59 1.9 133 4.0 106 2.4 41 81 5.7 2.4 7.39 40.0 86.9 41.9 24.7 217.2 5.6 2 42 
31.3 2700 65/28/7 52 10.0 0.78 87 2.5 130 4.7 119 3.2 41 44 6.1 3.1 7.42 21.0 93.4 40.5 25.8 444.8 4.9 3 37 
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26.9 3600 64/28/8 37 8.6 2.64 97 3.0 133 3.1 90 0.6 66 38 8.0 4.6 7.05 21.0 91.2 44.0 14.1 434.5 4.7 2 46 
34.9 13200 69/23/8 47 11.2 0.97 61 1.1 132 3.3 172 1.9 77 76 6.8 3.5 7.16 40.0 79.1 40.5 15.3 197.8 6.0 4 36 
30.7 12200 74/22/4 73 9.8 1.84 33 0.8 141 4.4 88 1.0 42 99 6.5 3.5 7.34 21.0 92.2 40.7 21.2 439.0 2.0 0 25 
27.5 12120 74/22/4 42 8.8 0.88 48 1.2 128 4.7 102 1.8 71 99 5.8 2.9 7.19 21.0 93.5 53.8 21.2 445.1 6.4 2 29 
38.8 16000 66/28/6 39 12.4 1.67 41 0.9 145 4.5 92 0.9 46 56 5.6 3.0 7.24 21.0 87.6 53.2 22.9 417.3 2.8 0 35 
26.9 12120 72/23/5 23 8.6 1.24 41 0.7 146 4.2 120 1.1 66 56 6.8 3.7 7.28 21.0 86.8 45.0 20.9 413.1 1.3 0 35 
35.2 11440 74/22/4 20 11.2 0.90 38 1.1 143 3.0 101 0.7 45 90 6.2 3.8 7.37 21.0 92.5 38.0 21.4 440.4 2.0 0 26 
26.9 11400 70/26/4 41 8.6 0.89 52 1.3 146 3.8 86 2.3 67 48 6.0 2.6 7.12 40.0 84.8 43.0 15.1 212.1 5.9 2 36 
35.1 12360 68/26/6 25 11.2 1.65 37 1.0 130 4.5 93 1.1 67 93 5.9 2.9 7.31 21.0 90.6 38.9 19.1 431.5 3.9 0 30 
35.0 12800 62/32/6 38 11.2 1.98 49 0.9 139 3.5 70 0.9 61 40 5.5 2.0 7.20 21.0 91.3 63.1 16.2 435.0 3.6 0 39 
35.1 11400 61/35/4 21 11.2 1.86 70 1.5 138 2.8 91 1.5 64 62 8.3 4.9 7.12 40.0 93.6 46.3 16.3 234.0 6.6 2 35 
38.5 12520 62/32/6 19 12.3 1.46 74 1.8 129 3.4 117 0.6 71 42 6.9 4.5 7.42 40.0 94.6 40.6 25.9 236.6 4.9 2 35 
36.3 12400 79/15/6 13 11.6 1.60 36 0.9 146 4.5 119 1.0 63 62 6.9 3.4 7.30 21.0 70.4 51.9 24.7 335.5 4.1 0 33 
32.6 16600 74/22/4 19 10.4 1.40 33 0.8 132 3.0 104 0.9 33 73 7.0 4.4 7.39 21.0 86.2 34.0 19.9 410.3 1.7 0 33 
27.5 12160 69/26/5 41 8.8 1.11 62 2.3 142 4.2 134 0.8 42 37 7.6 3.9 7.33 21.0 89.7 47.5 24.4 427.1 3.1 0 37 
35.0 12128 62/32/6 34 11.2 1.91 59 1.0 145 3.4 212 1.5 83 98 7.6 4.7 7.20 21.0 82.2 58.1 23.4 391.4 5.2 2 32 
22.5 12160 64/28/8 73 7.2 1.17 87 2.7 137 4.4 113 5.2 83 58 5.1 2.4 7.43 40.0 73.3 36.7 23.6 183.1 4.7 3 34 
37.6 11720 72/23/5 38 12.0 0.78 59 0.8 136 3.1 108 1.1 32 47 6.7 3.2 7.35 21.0 92.0 38.0 20.4 438.1 3.2 0 26 
27.9 12480 70/27/3 53 8.9 2.53 39 0.9 145 4.0 90 0.9 56 88 7.1 3.4 7.39 21.0 95.0 40.0 23.6 452.4 3.6 0 26 
41.3 15600 68/26/6 41 13.2 1.34 40 1.6 130 3.7 208 1.1 49 40 6.2 3.1 7.22 21.0 88.6 48.9 20.2 422.1 4.4 2 38 
38.8 13200 59/31/10 52 12.4 1.02 162 4.0 145 3.8 147 1.6 79 67 5.8 2.6 7.11 40.0 95.4 44.1 15.4 238.5 5.6 3 51 
38.8 13600 74/22/4 40 12.4 2.73 54 0.9 137 3.6 111 0.9 61 77 5.9 3.4 7.40 21.0 90.5 41.4 24.6 431.0 1.8 0 25 
32.2 3300 70/27/3 46 10.3 2.19 89 2.4 133 3.1 287 3.0 76 77 6.0 2.7 7.19 40.0 79.1 50.7 19.9 197.7 6.2 2 45 
27.5 14400 62/32/6 66 8.8 2.73 42 2.1 146 3.1 190 1.1 44 73 6.0 3.8 7.38 21.0 91.3 44.0 25.4 435.0 2.9 0 32 
34.9 13000 70/27/3 38 11.2 2.20 72 1.4 141 3.0 100 0.9 71 48 6.9 3.1 7.54 21.0 90.3 32.0 29.0 430.1 5.6 1 37 
30.7 14200 76/22/2 37 9.8 2.21 46 2.9 138 3.1 74 2.0 66 80 5.2 2.3 7.36 40.0 77.7 37.8 20.7 194.2 4.4 2 53 
33.9 12400 66/28/7 30 10.8 1.64 35 1.0 129 4.2 102 1.2 44 69 6.3 3.9 7.34 21.0 94.1 48.9 25.3 448.0 3.0 0 26 
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40.1 14400 70/27/3 16 12.8 1.14 39 0.6 146 2.9 114 0.8 61 41 5.9 3.1 7.36 21.0 89.6 42.0 23.0 426.7 3.7 0 31 
41.3 12200 72/23/5 21 13.2 2.34 36 1.0 144 3.7 76 3.1 143 157 5.6 2.8 7.27 40.0 87.0 44.4 20.2 217.4 6.6 3 28 
33.2 11520 64/28/8 27 10.6 1.94 56 1.6 130 4.6 240 1.0 53 43 6.2 2.8 7.10 40.0 82.1 56.4 19.2 205.4 4.2 2 33 
32.6 12152 61/32/7 21 10.4 1.74 40 1.0 130 3.6 104 1.1 40 74 6.8 3.6 7.33 21.0 91.4 45.6 23.4 435.2 2.4 0 28 
35.1 12040 69/23/8 15 11.2 1.08 35 0.9 136 4.5 148 0.6 31 41 5.7 3.0 6.91 21.0 95.9 57.4 15.5 456.5 3.1 0 29 
30.7 12600 80/13/7 26 9.8 1.59 46 0.7 141 4.3 106 0.5 58 43 6.5 3.5 7.02 21.0 84.6 43.0 13.2 402.8 2.0 0 29 
32.6 12120 74/22/4 56 10.4 0.95 47 1.4 136 4.6 101 2.0 85 40 7.2 3.3 7.36 21.0 94.0 32.4 17.7 447.6 5.0 1 27 
30.7 12104 66/23/11 39 9.8 1.88 58 2.9 143 3.6 101 0.8 35 76 7.5 4.2 7.21 21.0 90.8 48.9 20.0 432.4 3.1 0 30 
35.1 12200 65/28/7 29 11.2 2.41 76 3.4 132 3.7 96 0.7 39 93 7.3 3.8 7.24 21.0 85.7 43.2 18.4 408.0 2.6 0 32 
31.3 12400 82/15/3 49 10.0 0.98 39 0.9 129 3.0 159 1.2 45 73 6.2 3.5 7.16 21.0 87.0 44.6 16.7 414.1 4.0 0 35 
31.3 14300 74/22/4 65 10.0 0.88 95 2.3 146 3.0 84 1.5 71 71 6.2 3.7 7.21 40.0 70.1 51.0 20.8 175.3 6.7 3 42 
38.5 2700 74/22/4 37 12.3 2.48 56 0.9 138 4.6 153 1.3 61 80 7.3 3.3 7.30 21.0 91.0 42.7 20.7 433.2 2.9 0 33 
40.7 11520 70/27/3 51 13.0 1.22 31 0.8 137 3.6 102 1.0 36 75 6.2 3.9 7.30 21.0 92.3 39.7 19.0 439.5 3.2 0 25 
35.1 13800 66/28/6 56 11.2 1.41 43 1.1 146 3.7 171 0.9 45 97 7.1 3.0 7.35 21.0 91.0 43.0 22.9 433.3 3.1 0 33 
35.2 12040 74/22/4 41 11.3 1.29 35 0.9 143 3.9 117 1.6 79 96 7.0 4.3 7.40 40.0 88.0 28.0 17.0 219.9 4.9 2 24 
26.0 2700 69/26/5 28 8.3 0.96 104 2.3 135 3.5 143 3.4 96 43 5.0 2.2 7.36 40.0 84.1 41.7 22.8 210.2 5.0 4 44 
35.1 12600 61/32/7 20 11.2 1.36 55 1.9 140 4.0 145 2.2 71 76 7.2 3.9 6.97 40.0 85.0 47.6 13.8 212.5 6.1 2 39 
35.0 11440 66/28/7 28 11.2 1.45 91 2.3 139 4.6 94 0.7 56 54 6.2 2.5 7.23 21.0 90.0 36.2 15.3 428.6 5.8 2 36 
40.7 12800 66/28/6 14 13.0 1.43 41 1.0 144 4.1 112 1.3 50 64 6.1 3.4 7.32 21.0 94.0 39.0 19.6 447.6 3.1 0 29 
36.3 12176 74/22/4 44 11.6 2.48 31 0.9 138 3.3 150 0.7 52 94 6.9 4.3 7.42 21.0 86.4 39.3 24.5 411.4 3.4 0 31 
35.0 12200 64/32/4 72 11.2 2.35 40 1.2 136 4.0 117 0.9 42 73 6.4 3.1 7.47 21.0 83.3 35.2 25.5 396.6 2.5 0 24 
41.3 13800 82/15/3 16 13.2 1.43 51 1.7 145 4.1 102 2.6 88 39 6.2 2.8 7.22 40.0 83.1 41.0 16.9 207.8 4.2 1 34 
40.1 12320 74/22/4 14 12.8 1.73 31 0.7 145 4.2 92 1.3 41 44 6.7 3.2 7.36 21.0 91.4 42.9 23.2 435.1 2.5 0 27 
35.7 13000 74/22/4 34 11.4 1.27 43 0.9 134 2.9 117 2.9 53 63 6.1 3.6 7.41 21.0 91.3 40.5 25.2 434.8 1.9 0 28 
35.2 11920 74/22/4 43 11.2 0.87 71 1.7 128 4.7 119 2.3 78 84 7.0 3.5 7.18 40.0 85.3 54.1 21.1 213.3 5.3 3 33 
31.3 11680 79/15/6 39 10.0 1.91 77 1.5 137 4.2 88 3.7 84 44 5.6 2.3 7.33 40.0 85.4 32.0 16.3 213.6 5.6 3 34 
33.9 3100 61/35/4 27 10.8 1.47 41 1.1 146 3.1 175 3.2 73 68 6.1 3.2 7.04 40.0 86.8 41.0 13.0 216.9 4.6 4 51 
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34.9 12136 74/22/4 33 11.2 0.88 93 2.4 128 3.6 124 1.5 82 69 6.9 3.7 7.50 40.0 82.2 27.9 22.5 205.4 4.1 2 37 
35.2 2120 64/28/8 30 11.2 0.92 82 2.2 137 3.3 90 1.7 47 78 6.1 3.3 7.36 21.0 91.9 32.0 17.3 437.6 6.0 3 31 
26.6 14200 64/28/8 61 8.5 1.29 54 1.3 129 4.0 109 3.0 70 38 6.9 3.0 7.39 40.0 87.7 37.5 22.0 219.1 4.4 2 36 
31.3 12440 69/23/8 20 10.0 2.67 52 2.0 144 3.4 120 0.8 60 53 6.0 3.7 7.26 40.0 85.9 47.4 21.0 214.7 4.5 2 35 
40.7 12192 65/28/7 14 13.0 0.90 54 2.0 143 4.3 91 2.3 72 35 5.4 2.6 7.49 40.0 89.4 30.1 23.1 223.5 5.1 3 36 
34.9 12144 82/15/3 41 11.2 2.86 39 1.1 130 3.8 121 1.1 32 59 6.3 3.2 7.43 21.0 95.1 33.2 21.6 452.7 1.7 0 35 
40.7 14,300 81/17/2 13 13.0 0.36 42 1.2 126 3.4 109 1.5 55 64 5.8 2.9 7.29 40.0 88.0 30.0 14.0 220.0 4.9 3 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
C
u
lt
u
re
/ 
Se
n
si
ti
vi
ty
 
M
P
/M
F 
M
SA
T 
Ig
M
/I
gG
 D
en
gu
e 
W
id
al
 T
es
t 
O
S 
in
fe
ct
ed
 
C
o
m
o
rb
id
 O
S 
C
at
eg
o
ry
 
C
o
m
p
le
te
 D
ia
gn
o
si
s 
O
u
tc
o
m
e 
B
lo
o
d
 
U
ri
n
e 
C
SF
 
W
o
u
n
d 
Sp
u
tu
m
 
O
th
er
s 
47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 
NG E.Coli × × × ×   ve   ve   ve   ve GUT CNS SIRS/Sepsis CIDP/ Dis 
NG × × × × ×   ve   ve   ve   ve GIT HB SevSepsis DCLD/PHT/SBP/HE Dis 
CONS × × × NG ×   ve   ve   ve   ve RS CNS SIRS/Sepsis Seiz dis Dis 
P.Vulg P.Vulg × × × ×   ve   ve   ve   ve GUT MOS SS DMT2/SHT/CVA/UTI Dis 
NG × × × × ×   ve   ve   ve ₊ ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG × × × Comm ×   ve   ve   ve   ve RS Nil SIRS/Sepsis BrPn Dis 
CONS × × × × ×   ve   ve   ve ₊ ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG × × × × × ₊ ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
NG × × × NG ×   ve   ve   ve   ve RS CNS SIRS/Sepsis HyKPP/AspPn Dis 
NG × × × NG ×   ve   ve   ve   ve RS CNS SevSepsis Psychosis/BA Dis 
NG × NG × × × ₊ve   ve   ve   ve TropInf MOS SevSepsis DMT2/Cbl Mal Dis 
NG × × × NG ×   ve   ve   ve   ve RS Hem SevSepsis CML/BrPn Dis 
NG × × × × ×   ve   ve   ve   ve GIT Nil SIRS/Sepsis AGE/ Dis 
NG × × × × NG   ve   ve   ve   ve GIT HB SS DCLD/PHT/SBP Dis 
NG × × × × ×   ve   ve   ve   ve RS MOS SevSepsis BrPn/SHT Dis 
NG × × × × ×   ve   ve   ve   ve RS CNS SIRS/Sepsis CVA/SeizDis Dis 
NG × × × NG ×   ve   ve   ve   ve RS CNS SevSepsis Young CVA/AspPn Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
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S.Aures × × × NG ×   ve   ve   ve   ve RS MOS SIRS/Sepsis SHT/RA/ILD Dis 
NG × × × × ×   ve   ve   ve   ve RS MOS SevSepsis COPD/SHT/CHF Death 
CONS × × × Comm ×   ve   ve   ve   ve RS RS SIRS/Sepsis BA/SHT Dis 
NG × × × × ×   ve ₊ve   ve   ve TropInf Nil SIRS/Sepsis lepto Dis 
NG NG × × × ×   ve   ve   ve   ve GUT MOS SIRS/Sepsis DMT2/PyNeph Dis 
NG × × × × ×   ve ₊ve   ve ₊ve TropInf Nil SevSepsis Lepto/EntFev/ Dis 
NG × × × × NG   ve   ve   ve   ve GIT HB SIRS/Sepsis DCLD/PHT/SBP Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS DMT2/SHT/CKD Dis 
NG × × × × ×   ve   ve   ve   ve Occult Hem SS HELLP Synd Death 
NG × × × × ×   ve   ve ₊ve   ve TropInf Nil SevSepsis dengue Dis 
NG × × × NG ×   ve   ve   ve   ve RS RS SIRS/Sepsis ChrBritis/ Dis 
NG × × × CONS ×   ve   ve   ve   ve RS CNS SS Seiz;AspPn; Dis 
NG × × × M.Plasma ×   ve   ve   ve   ve RS MOS SIRS/Sepsis Psychosis/PTb Seq Dis 
CitroB × × × × ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis DMT2/SHT/CKD Dis 
NG NG × × × ×   ve   ve   ve   ve GUT MOS SevSepsis DMT2/SHT/UTI Dis 
CONS CONS × × × ×   ve   ve   ve   ve GUT CVS SIRS/Sepsis PpCMP/CHF Dis 
NG NG × × × ×   ve   ve   ve   ve GUT MOS SS DMT1;UTI Death 
S.Aureus × × × S.Aureus ×   ve   ve   ve   ve RS RS SevSepsis Bronchiectasis Dis 
S.Typhi × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
MRSA × NG MRSA × ×   ve   ve   ve   ve CNS CNS SevSepsis CSOM;AcMenEn Dis 
NG E.Coli × × × ×   ve   ve   ve   ve GUT MOS SIRS/Sepsis DMT1;UTI Dis 
Klebs × × × Klebs ×   ve   ve   ve   ve RS MOS SevSepsis SHT/CAD/BrPn Death 
NG × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis SHT;CVA; Dis 
NG × × × × ×   ve   ve   ve   ve Occult CVS SevSepsis RHD/CHF Dis 
NG × × × × ×   ve   ve   ve   ve RS CNS SevSepsis CVA;AspPn Dis 
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NG × × × NG ×   ve   ve   ve   ve RS RS SIRS/Sepsis Tb Seq/Cavity Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS DMT2;DKA Dis 
NG × × × S.Pneum ×   ve   ve   ve   ve RS Nil SevSepsis CABPn Dis 
NG NG × × × ×   ve   ve   ve   ve GUT Nil SIRS/Sepsis UTI Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis DMT2/SHT/CVA Death 
NG NG × × NG ×   ve   ve   ve   ve RS MOS SIRS/Sepsis SHT/CAD/CKD Death 
NG × × × × ×   ve   ve   ve   ve Occult CVS SIRS/Sepsis CHD/ASD Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS SHT;CVA; Death 
NG × × × NG ×   ve   ve   ve   ve RS Nil SevSepsis BrPn Dis 
NG × NG × × ×   ve   ve   ve   ve CNS Nil SevSepsis AcMenEnc Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SevSepsis Cbl Malaria Dis 
E.coli NG × × × ×   ve   ve   ve   ve GUT Nil SIRS/Sepsis PID/UTI Dis 
NG × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG × × × × ×   ve   ve ₊ve   ve TropInf Nil SevSepsis dengue Dis 
NG × × × × ×   ve   ve   ve   ve Occult GIT SIRS/Sepsis Gastritis Dis 
NG NG × × NG ×   ve ₊ve   ve ₊ve TropInf MOS SevSepsis SHT/Lepto/Ent Fev Dis 
EntCoccos × × × × ×   ve   ve   ve   ve Occult Hem SS CML; Death 
NG × × × × ×   ve   ve   ve   ve Occult CVS SS RHD/CHF Dis 
Klebs NG × × NG ×   ve   ve   ve   ve RS MOS SevSepsis DMT2;SHT;CAD;CHF Death 
NG × × × × ×   ve   ve   ve   ve Occult CVS SIRS/Sepsis SHT/CAD Dis 
S.Aureus × × × × NG   ve   ve   ve   ve GIT GUT SevSepsis Nephrotic synd Dis 
NG E.Coli × × × ×   ve   ve   ve   ve GUT CNS SS CVA/UTI Dis 
NG NG × × × ×   ve   ve   ve   ve GUT MOS SIRS/Sepsis SLE/Lupus nephritis Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS SHT;CVA; Dis 
CONS × × NG × ×   ve   ve   ve   ve Skin MOS SS SHT;CVA;BedSore Dis 
NG NG × × × NG   ve   ve   ve   ve Occult MOS SevSepsis SLE/CKD/Vol OvLoad Death 
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NG × × × × ×   ve   ve   ve   ve Occult MOS SevSepsis DMT2;SHT;CAD;CHF Death 
Klebs × × × × ×   ve   ve   ve   ve Occult Hem SIRS/Sepsis F XIII def/Hematoma Dis 
NG × × × PTb/Comm ×   ve   ve   ve   ve RS RS SevSepsis Active PTb/FibCav Dis 
Klebs NG NG × NG ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis SHT/SeizDis/ Dis 
Acineto × NG × × ×   ve   ve   ve   ve CNS RS SIRS/Sepsis COPD/ Dis 
CONS × × × × ×   ve   ve   ve   ve TropInf Nil SIRS/Sepsis dengue Dis 
NG × × × × ×   ve   ve   ve   ve Occult HB SevSepsis DCLD/PHT/SBP Dis 
S.Aureus × × × × NG   ve   ve   ve   ve GIT HB SIRS/Sepsis EHPVO/PHT/SBP Dis 
E.Coli × × × × ×   ve   ve   ve   ve GIT HB SIRS/Sepsis DCLD/PHT/SBP Death 
NG × × × × ×   ve   ve   ve   ve Occult CVS SevSepsis RHD/CHF Dis 
NG × × × × ×   ve   ve   ve   ve Skin CNS SevSepsis GBS/BedSore Dis 
CONS × NG × × ×   ve   ve   ve   ve CNS Nil SIRS/Sepsis AcMenEnc Dis 
NG × × × × ×   ve   ve   ve   ve Occult RS SIRS/Sepsis COPD Dis 
NG NG × × × ×   ve   ve   ve   ve GUT Malig SIRS/Sepsis CaCX/UTI death 
S.Aureus × × × × ×   ve   ve   ve   ve Skin MOS SevSepsis DMT2;Cellulitis Dis 
E.Coli E.Coli × × × ×   ve   ve   ve   ve GUT CNS SS CVA;UTI Dis 
NG × × × × ×   ve   ve ₊ve   ve TropInf Nil SIRS/Sepsis dengue Dis 
NG × × × × ×   ve   ve   ve   ve Occult Hem SIRS/Sepsis Thallesemia Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS DMT2;SHT;CAD;CHF Dis 
S.Aureus NG × × NG ×   ve   ve   ve   ve Occult MOS SS DMT2;SHT;CKD Death 
NG × × × × ×   ve ₊ve   ve   ve TropInf Nil SIRS/Sepsis Lepto Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SevSepsis DMT2;DKA;AspPn; Death 
Acineto NG × × NG ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis DMT2;CAD Dis 
CONS × × × Klebs ×   ve   ve   ve   ve RS Malig SevSepsis CaEso/Collapse lung Dis 
NG × × × × ×   ve   ve   ve   ve GIT HB SS DCLD/PHT/SBP Dis 
NG × × × Klebs ×   ve   ve   ve   ve RS Nil SIRS/Sepsis CABPn Dis 
S.Typhi × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
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E.coli × × E.Coli × ×   ve   ve   ve   ve HB Nil SS Liver Abscess Dis 
               Pseudo × × × Pseudo ×   ve   ve   ve   ve RS MOS SevSepsis DMT2;BrPn Death 
NG × × × NG ×   ve   ve   ve   ve RS RS SIRS/Sepsis Tb Seq/Cavity Dis 
S.Aureus NG × × NG ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis DMT2/DKA/ Death 
S.Aureus × × × S.Aureus ×   ve   ve   ve   ve RS Nil SIRS/Sepsis CABPn Dis 
NG × × × × ×   ve   ve   ve   ve Skin MOS SevSepsis SHT/Cellulitis leg Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
Acineto × × × × ×   ve   ve   ve ₊ve TropInf Nil SIRS/Sepsis Ent Fev/ Dis 
NG NG × × NG ×   ve   ve   ve   ve RS MOS SIRS/Sepsis COPD/DMT2 Dis 
NG × × × × NG   ve   ve   ve   ve GIT HB SevSepsis DCLD/PHT/SBP Dis 
NG × × × × NG   ve   ve   ve   ve GIT HB SIRS/Sepsis CLD/SHT/SBP Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis DMT2/DCMP/CHF Death 
NG × × × NG ×   ve   ve   ve   ve RS Nil SevSepsis BrPn Dis 
NG × × × × NG   ve   ve   ve   ve GIT MOS SS DMT2;DCLD/PHT/UGIB; Death 
NG × × × × ×   ve   ve   ve   ve Occult MOS SevSepsis DMT2;SHT;CAD;CHF Death 
Pseudo Candida × × × ×   ve   ve   ve   ve GUT MOS SevSepsis Tb Seq/CAD/UTI Dis 
CONS × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
Acineto × × × NG ×   ve   ve   ve   ve RS MOS SIRS/Sepsis BA/DMT2 Dis 
S.Aureus × × × CONS ×   ve   ve   ve   ve RS Nil SIRS/Sepsis CABrPn Dis 
CONS × × × Comm ×   ve   ve   ve   ve RS Nil SevSepsis BrPn Dis 
NG × × × × × ₊ve   ve   ve   ve TropInf Nil SIRS/Sepsis Malaria Dis 
NG × × × × ×   ve ₊ve   ve   ve TropInf Nil SIRS/Sepsis Lepto Dis 
NG × × × × ×   ve   ve   ve   ve Occult CVS SS RHD/CHF Dis 
NG × × × × NG   ve   ve   ve   ve GIT HB SevSepsis DCLD/PHT/UGIB Dis 
NG × × × × ×   ve   ve   ve   ve Occult MOS SS DMT2/SHT/CAD/CVA Death 
NG × × Pseudo × ×   ve   ve   ve   ve RS Nil SevSepsis Empyema/ Dis 
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NG × × × × ×   ve   ve   ve   ve GIT Nil SS AGE/ Dis 
NG × NG × × × ₊ve   ve   ve   ve TropInf Nil SS Cbl Malaria Dis 
Pseudo × × × NG ×   ve   ve   ve   ve RS MOS SS RHD/Embolic CVA Dis 
Pseudo/ 
S.Aureus 
× × × NG ×   ve   ve   ve   ve RS ImmSup SevSepsis HIV/BrEctasis Dis 
CONS × × × × ×   ve   ve   ve   ve Occult MOS SIRS/Sepsis SHT;CVA; Dis 
NG × × × Klebs ×   ve   ve   ve   ve RS MOS SevSepsis SHT;CAD;BrPn Dis 
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